JP2022520553A - ラクトバチルス・ロイテリ(Lactobacillus Reuteri)菌株を含むプロバイオティック組成物及び使用方法 - Google Patents
ラクトバチルス・ロイテリ(Lactobacillus Reuteri)菌株を含むプロバイオティック組成物及び使用方法 Download PDFInfo
- Publication number
- JP2022520553A JP2022520553A JP2021546018A JP2021546018A JP2022520553A JP 2022520553 A JP2022520553 A JP 2022520553A JP 2021546018 A JP2021546018 A JP 2021546018A JP 2021546018 A JP2021546018 A JP 2021546018A JP 2022520553 A JP2022520553 A JP 2022520553A
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- composition
- lactobacillus reuteri
- seq
- poultry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000186604 Lactobacillus reuteri Species 0.000 title claims abstract description 178
- 239000000203 mixture Substances 0.000 title claims abstract description 173
- 229940001882 lactobacillus reuteri Drugs 0.000 title claims abstract description 128
- 238000000034 method Methods 0.000 title claims abstract description 24
- 239000006041 probiotic Substances 0.000 title abstract description 10
- 230000000529 probiotic effect Effects 0.000 title abstract description 10
- 235000018291 probiotics Nutrition 0.000 title abstract description 10
- 241001465754 Metazoa Species 0.000 claims abstract description 76
- 230000036541 health Effects 0.000 claims abstract description 29
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 28
- 230000002708 enhancing effect Effects 0.000 claims abstract description 14
- 244000144977 poultry Species 0.000 claims description 45
- 150000007523 nucleic acids Chemical group 0.000 claims description 38
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 25
- 244000052769 pathogen Species 0.000 claims description 25
- 230000001717 pathogenic effect Effects 0.000 claims description 21
- 241000287828 Gallus gallus Species 0.000 claims description 17
- 244000005700 microbiome Species 0.000 claims description 15
- 241000607142 Salmonella Species 0.000 claims description 12
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 12
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 229960005486 vaccine Drugs 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 9
- 230000001965 increasing effect Effects 0.000 claims description 9
- 230000003902 lesion Effects 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- 241000186660 Lactobacillus Species 0.000 claims description 8
- 239000007921 spray Substances 0.000 claims description 8
- 241000193468 Clostridium perfringens Species 0.000 claims description 7
- 241000282414 Homo sapiens Species 0.000 claims description 7
- 244000052616 bacterial pathogen Species 0.000 claims description 7
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 claims description 7
- 241000607128 Salmonella enterica subsp. enterica serovar Infantis Species 0.000 claims description 6
- 241000194017 Streptococcus Species 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 241000589876 Campylobacter Species 0.000 claims description 5
- 208000003495 Coccidiosis Diseases 0.000 claims description 5
- 206010023076 Isosporiasis Diseases 0.000 claims description 5
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 claims description 5
- 241000191967 Staphylococcus aureus Species 0.000 claims description 5
- 108700003601 dimethylglycine Proteins 0.000 claims description 5
- 229960000367 inositol Drugs 0.000 claims description 5
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 5
- 229940039696 lactobacillus Drugs 0.000 claims description 5
- 230000001737 promoting effect Effects 0.000 claims description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 4
- 241000193403 Clostridium Species 0.000 claims description 4
- 108010016626 Dipeptides Proteins 0.000 claims description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims description 4
- 229960003237 betaine Drugs 0.000 claims description 4
- 125000004122 cyclic group Chemical group 0.000 claims description 4
- 239000003797 essential amino acid Substances 0.000 claims description 4
- 235000020776 essential amino acid Nutrition 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 206010051606 Necrotising colitis Diseases 0.000 claims description 3
- 241001437644 Salmonella enterica subsp. enterica serovar Kentucky Species 0.000 claims description 3
- 241001546666 Salmonella enterica subsp. enterica serovar Newport Species 0.000 claims description 3
- 241000191940 Staphylococcus Species 0.000 claims description 3
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 3
- 239000003674 animal food additive Substances 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 3
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 3
- 150000004666 short chain fatty acids Chemical class 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 241000606125 Bacteroides Species 0.000 claims description 2
- 230000037396 body weight Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 235000021391 short chain fatty acids Nutrition 0.000 claims 2
- 208000004232 Enteritis Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 235000013594 poultry meat Nutrition 0.000 description 26
- 239000002609 medium Substances 0.000 description 17
- 239000006228 supernatant Substances 0.000 description 14
- 238000003501 co-culture Methods 0.000 description 13
- 241000271566 Aves Species 0.000 description 10
- 235000013330 chicken meat Nutrition 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000002257 embryonic structure Anatomy 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 6
- 238000000513 principal component analysis Methods 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000012447 hatching Effects 0.000 description 5
- 210000000936 intestine Anatomy 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 150000003272 mannan oligosaccharides Chemical class 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- AYFVYJQAPQTCCC-UHFFFAOYSA-N THREONINE Chemical compound CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- -1 arabinoxylan oligosaccharides Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000589875 Campylobacter jejuni Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000006872 mrs medium Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- POMORUSPLDFVEK-PHXAWWDYSA-N (4r)-5-[[(2s,3s)-1-[[(2s)-6-amino-1-[[(2r)-5-amino-1-[[(2s,3s)-1-[[(2r)-1-[[(2s)-1-[[(2r)-1-[[(1s)-3-amino-1-carboxy-3-oxopropyl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methy Chemical compound OC1=CC=CC=C1C(=O)OCOC(=O)C1=CC=CC=C1O.C1SC(C(N)C(C)CC)=NC1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=CC=C1 POMORUSPLDFVEK-PHXAWWDYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- 101710133359 Agglutinin receptor Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 235000019783 Bacitracin Methylene Disalicylate Nutrition 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- 241000605952 Fusobacterium necrophorum Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 229920000617 arabinoxylan Polymers 0.000 description 2
- 229940032022 bacitracin methylene disalicylate Drugs 0.000 description 2
- 108010054309 bacitracin methylenedisalicylic acid Proteins 0.000 description 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000024321 chromosome segregation Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 2
- IERHLVCPSMICTF-UHFFFAOYSA-N cytidine monophosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(O)=O)O1 IERHLVCPSMICTF-UHFFFAOYSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- ZOAMBXDOGPRZLP-UHFFFAOYSA-N indole-3-acetamide Chemical compound C1=CC=C2C(CC(=O)N)=CNC2=C1 ZOAMBXDOGPRZLP-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000002705 metabolomic analysis Methods 0.000 description 2
- 230000001431 metabolomic effect Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 239000001053 orange pigment Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- RILPIWOPNGRASR-RFZPGFLSSA-N (2R,3R)-2-hydroxy-3-methylpentanoic acid Chemical compound CC[C@@H](C)[C@@H](O)C(O)=O RILPIWOPNGRASR-RFZPGFLSSA-N 0.000 description 1
- HLXXMJDWTBXTOR-STQMWFEESA-N (3s,6s)-3-benzyl-6-(1h-imidazol-5-ylmethyl)piperazine-2,5-dione Chemical compound C([C@@H]1NC([C@@H](NC1=O)CC=1NC=NC=1)=O)C1=CC=CC=C1 HLXXMJDWTBXTOR-STQMWFEESA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- ZHCKPJGJQOPTLB-UHFFFAOYSA-N 1-methyl-4-imidazoleacetic acid Chemical compound CN1C=NC(CC(O)=O)=C1 ZHCKPJGJQOPTLB-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- LVRFTAZAXQPQHI-UHFFFAOYSA-N 2-hydroxy-4-methylvaleric acid Chemical compound CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 description 1
- QZBUWPVZSXDWSB-UHFFFAOYSA-N 3-benzyl-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Chemical compound O=C1N2CCCC2C(=O)NC1CC1=CC=CC=C1 QZBUWPVZSXDWSB-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- WXSKVKPSMAHCSG-UHFFFAOYSA-N 4-hydroxy-2-oxoglutaric acid Chemical compound OC(=O)C(O)CC(=O)C(O)=O WXSKVKPSMAHCSG-UHFFFAOYSA-N 0.000 description 1
- JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 1
- 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
- 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 241000606126 Bacteroidaceae Species 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 101710150468 C protein alpha-antigen Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010073254 Colicins Proteins 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 244000087226 Conyza maxima Species 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- 101710191940 D-gamma-glutamyl-meso-diaminopimelic acid endopeptidase CwlS Proteins 0.000 description 1
- FNZLKVNUWIIPSJ-RFZPGFLSSA-N D-xylulose 5-phosphate Chemical compound OCC(=O)[C@@H](O)[C@H](O)COP(O)(O)=O FNZLKVNUWIIPSJ-RFZPGFLSSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- XXEWFEBMSGLYBY-ZETCQYMHSA-N N(6),N(6)-dimethyl-L-lysine Chemical compound CN(C)CCCC[C@H](N)C(O)=O XXEWFEBMSGLYBY-ZETCQYMHSA-N 0.000 description 1
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
- 101710202699 N-acetylmuramoyl-L-alanine amidase sle1 Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- CIQHWLTYGMYQQR-QMMMGPOBSA-N O(4')-sulfo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OS(O)(=O)=O)C=C1 CIQHWLTYGMYQQR-QMMMGPOBSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 102000008153 Peptide Elongation Factor Tu Human genes 0.000 description 1
- 108010049977 Peptide Elongation Factor Tu Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- NOKPBJYHPHHWAN-REOHCLBHSA-N S-sulfo-L-cysteine Chemical compound OC(=O)[C@@H](N)CSS(O)(=O)=O NOKPBJYHPHHWAN-REOHCLBHSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241001355131 Salmonella enterica subsp. enterica serovar Hadar Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000194021 Streptococcus suis Species 0.000 description 1
- 241000194054 Streptococcus uberis Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000004182 Tylosin Substances 0.000 description 1
- 229930194936 Tylosin Natural products 0.000 description 1
- 238000001790 Welch's t-test Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 210000001643 allantois Anatomy 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 description 1
- 229960004797 cefpodoxime proxetil Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 108010038252 cyclo(phenylalanyl-prolyl) Proteins 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- CLQUUOKNEOQBSW-KEGKUKQHSA-N erythromycin D Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@H]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)C)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 CLQUUOKNEOQBSW-KEGKUKQHSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- JBFYFLXEJFQWMU-WDSKDSINSA-N gamma-Glu-Gln Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(O)=O)CCC(N)=O JBFYFLXEJFQWMU-WDSKDSINSA-N 0.000 description 1
- 108010002568 gamma-glutamylglutamine Proteins 0.000 description 1
- 231100001014 gastrointestinal tract lesion Toxicity 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- PRJKNHOMHKJCEJ-UHFFFAOYSA-N imidazol-4-ylacetic acid Chemical compound OC(=O)CC1=CN=CN1 PRJKNHOMHKJCEJ-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000012067 mathematical method Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 208000037931 necrotizing enteritis Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000017448 oviposition Effects 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 description 1
- 229960000268 spectinomycin Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229940115922 streptococcus uberis Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 description 1
- 229960004885 tiamulin Drugs 0.000 description 1
- 229960000223 tilmicosin Drugs 0.000 description 1
- JTSDBFGMPLKDCD-XVFHVFLVSA-N tilmicosin Chemical compound O([C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CCN1C[C@H](C)C[C@H](C)C1)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@@H]1O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]1O JTSDBFGMPLKDCD-XVFHVFLVSA-N 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960004059 tylosin Drugs 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- 235000019375 tylosin Nutrition 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/173—Reuteri
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/335—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Lactobacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
Abstract
Description
本出願は、2019年2月5日に出願された米国仮特許出願第62/801,307号に対する優先権を主張するものであり、その内容が参照により本明細書に組み込まれる。
本出願は、EFS-WebによりASCII形式で提出した配列表を含み、その全体が参照により本明細書に組み込まれる。2020年2月4日に作成されたASCIIコピーの名称は、「X30027-SeqListing_ST25.txt」であり、サイズは121KBである。
本開示は、動物の健康を高める方法であって、有効量の組成物を動物に投与する工程を含む、方法も提供する。
配列番号1 メルサシジン-E1 cDNA
1 atggacaaag aagaattaga aaaaattgta ggtaataact ttgaggaaat gagtttacaa
61 aaaatgacag aaattcaagg tatgggtgaa taccaagtgg attcaacacc agcagcttct
121 gcgatttcac gggcaacaat tcaagtatca cgtgcatctt ctggaaaatg tctaagttgg
181 ggtagtggtg cagcatttag tgcttatttt actcataaaa gatggtgcta g
配列番号2 メルサシジン-E1アミノ酸(天然)
1 MDKEELEKIV GNNFEEMSLQ KMTEIQGMGE YQVDSTPAAS AISRATIQVS RASSGKCLSW
61 GSGAAFSAYF THKRWC
配列番号3 メルサシジン-E2 cDNA
1 atggaagaaa aagaattaga aggtgtaata gggaattcgt ttgaaagtat gactgtagag
61 gaaatgacaa aaattcaagg tatgggtgaa tatcaagtag attcgacgcc tggatatttt
121 atggaaagtg ctgccttttc agctcttaca gccaatataa caagacatgc tatgcatcat
181 cattaa
配列番号4 メルサシジン-E2アミノ酸(天然)
1 MEEKELEGVI GNSFESMTVE EMTKIQGMGE YQVDSTPGYF MESAAFSALT ANITRHAMHH
61 H
配列番号5 カプレオマイシジンシンターゼ(天然)。
1 MVEIAHFGVE AWLNKWEKSA TYDISQSTIA SLSMHDLLNL DGNNGEEFYE MLDKQQMNYG
61 WIEGSPEFKE EVAKLYHHVD PENILQTNGA TGANILALYA LINPGDHVIA EYPSYQQLYD
121 IPKSLGADVD YWHIHEEDNW YPRIDDLKAM VKPNTKMICL NNANNPTGTV LDKEFLEQVV
181 EIAKSVDAYV LVDEVYLPLD HPEKFAQIID LYDKGISTNS LSKTYSVPGV RIGWTATNAE
241 VADIFRKFRD YTMICGGVFN DQLATYVLRH RDQVLARNRK LVLGNLAIYK DWIDHEDRAS
301 VIMPQAVSTS FPKLDVPVDI HTFCENLLHD EGVLLVPGDA FDTPGHVRLG YCAPEATLKE
361 GLKRLSKYMH QYD
配列番号6 コリシンV産生タンパク質(天然)。
1 MILTTFIILI LMGCFINGHR RGLLTMTLML GTYIVAWIVA RQGAQLIGGW LKSLLPSIGT
61 PATFSESLLA NVNSNLFFYN GIAFMIIFTI VSILCHWGIR QLNWIKRIPV VGTVDKIAGG
121 LISFLIGYLI IYVVLLIMQL FPAGWWQMQI ANSELARFMI NQTPGIAHLV IDTLVQGG
配列番号7 凝集素受容体前駆体-1(ARP-1)(天然)
1 MNEYNAEMAK LNQGANAPVI TTNSVNQALS LKPENNATVD IEALNPRITF KRVEEGTKYA
61 GYQIFDKNNA YVNNIDGEFL RVTYTNLKNS TYKGSKISKI VVTYSDSTPT GNRITQSGLN
121 AVTEGANDNF LVVFEDPVRG DMHSTTVTAT YQYYDANGNL IDFSGTNNAW LSVGSLNFDQ
181 GNDYQGGKNE GNPTSGISEG VKLISGAQIK QLAGSSISVH DDGWAYAGFN NYSGTGMNNG
241 INTDNGGSGW DMDGSPNAYY GAIVFQLTGS SVSLRQGLVS WGGADIASQY NNQFLNNAWF
301 TAGTTLPETQ IKQPIRKTSE THYHYNPSVI RL
配列番号8 凝集素受容体前駆体-2(ARP-2)(天然)
1 MAQKLMSANS TDKNFKMYKS KKSWVFAYST TLALAAVAGI TLSTTNVHAD TTNGGDNQVN
61 ATAVTQNTTS NTVDQIAANT AQTDNTSTSI NIRSLMDDLA SGDDTSSSQN GQEQSQNYAS
121 SNQNSQTQQE NGTTGQSTAS QNGTTSDQTN SDQSDKNYYV ISTRDLDKNG NVNYLTQKNY
181 TSIKGQEVAD GTVVTWPLSV SALPANRAQD LKSHVISETL DPHLEYLHYR AYLTNTDGTV
241 TDVTNHVNLN RSGQTLIFTD DNYLLSIYNN NRYRVQNLPV IKLVTKANGN GYIIPNAFKS
301 SYVFNDGSHD VSFTTTSNNV QIKTFNPGNS KDVEIGGNVQ GDPSGTINGQ VVADGSVVTW
361 PMSVGDLPAN RAQDVLSHIE TDTLYNGLNY EGYHAYLPQA DGSFQDVSSH INVQQNGQDL
421 TFIADDYLIG LYNQDKSTAF KMPIIDLITS VHGTSIIAPN KFNSQLAFKD GNGQTVINNT
481 SNQVQISTYH PTNTKDVELG GNVQGDTPNS INDKVVANGA IVTWPMASSE LPANRVQDLQ
541 SRVISETLDS HLQYQGYKAW LQNADGKYTD VTSHVKLTQD GQNLTFADDE YLLNLYNSNK
601 GTAYKLPIID LVTKVNGAGI TAPNSYTTKY VYSDGDGNTT INVTSNTVKI STFNPTTNKD
661 VELGDNIHGD TESSIAGKLV SEGTIVTWPL STSDLPANRA QDVVSHTAVD ALEPTLQYIS
721 YTAWLPDSNG QLQDVTSHVK MTRDGQKLTF TDDDYLIGLY NQNKDIALKM PIIDLVTKAT
781 GNTKLLPNSF DSQFVYNDVD GNTIINVSSN KPTVETFDPT VHKDVELGGN NVQGDTPNSI
841 DGKIVAQGTV VTWPMSTSDL PANRTQDVVS HSTSETLNQN LQYVGYHAYM PDANGKLQDV
901 TSHVQLQQNG QNLVFTDDSY LINLYNQDKS IAFKMPIIDL MTKAISDSAT IPNTFESQYV
961 FNDGNGNTTF KSTSNTVQII TYKPKTTKDV ELGDNIHGDT NASIAGQMIT DGTVVTWPMS
1021 TSDLPANRTQ DLQQHVVTDN LNDNLIFQGY TAWLPTANGL VDVTNHIELT RDGQNLTFTD
1081 DAYLLNLYNQ NKDTAYKLPI IDLVTKANGN TKLIPNNFDS MFVYNDGDQQ TTVNVTSNTV
1141 NISTYDPTAT KDVELGDDIE GDTADTINNL MVQIGTKMTY PLTVSDLPAN RADEITAHQS
1201 VDTLSDYLEY QGYKAYLPDA DGKLQDITEH VNLKREGQKL SFNDDDYLIN LYNNSKATKQ
1261 ALPVIDLVAK VTGSNDGKKV HIIPNHFDST ITTKDGKINT TSNTVVINSN DPEAVKDVEL
1321 GDNVVGDTPN SVTGTTVADG TIVTWPMSVG SLGANRAQNV IKHTETENLD SGLTYLSFKA
1381 YLPDADGKMQ DITEHINIQQ DGQKLVFTDD DYLISLYNKD KSQRFALPVI DLVTRVNGDN
1441 KIIPNTFVSQ FTFNDGKGNT ITSVTSNQVN VSTFKSNPEK HVTLGTDIEG DDAENADGTV
1501 VAQGSEVTWP LSDKSPLPAN RSQDVKSHTL VDKLDDNLQY NSYKAYLKGT DGKLQDVTDH
1561 IKLTRDGQNL TFIDDDYLLD LYNKDKSTAF NLPIIDLVTT VVGNDKLIPN KFDSNFVFSD
1621 GNKDTSMKTT SNEVSISTYT PVTNKDAELG DNVVGDTSDS IANETVPDGT IVTWPLSVSS
1681 LPANRSQDVF KHVIEDILDG NLTYNSFKAY LKDAAGNLQE VTDHVKLAQE GQHLTFTDDD
1741 YLINLYNSSK NKEQSLPIID LVTTVHGDSK LIPNEFDNVF VFKDGKGQTT VKTTSNKVTI
1801 KTASLPTPTK EETDDQGNNI NGNEVKAGEH VNYTLNWDLS NDKDVKATPE MIKKGFFFID
1861 PIDSRALSVD DLSKAKVVDQ NGNKVDGISF HLYNSLSEVP EFIQEQVKAN NLQDKITGPF
1921 VVAQADDLQA FFDKYVKTGA KLKVTIPTIV KSGFTGEFSN TAYQFGFGKA TPTNTVTNYV
1981 KPMHKPASPE TPAAIAPQVI SATAQPMTSD APVTPSEKTA KLPQTGNADE GALLGLAAVS
2041 LVGSLGLAAL GLKQNRNDD
配列番号9 キシルロース-5-リン酸ホスホケトラーゼプロモーター(天然)
1 TTAAAGTATT AAAATAGATG TAAAATTTAT TTTTTTCAAA AGAAATTTTA ATTGTACACT
61 GTTGGTATTG AACGGGGTTA AACAAAGGTA AATTAGCATT TCTGCGGATT AAGATAAATA
121 GAAAAATGTT AAAGAACACC TTAAAAAGAT TAATTTTTTA TAATTGGACC GTATCAATTT
181 GTAAAAAGGT TGACTTTTTG AAAAAAAAGT TTATCATTAA CATTGTAAAT TTAATGATTT
241 ACGTTATGTT GTTATAGAGC ACAGGACGTA TTGATTTATA TAGAAGGAGT GTTTATTAGA
配列番号10 伸長因子TUプロモーター(天然)
1 ATGAATGGAC AGATGTTTTA ATCGCTAGAA TAGAAGGAAA GAAAGTCGCA ACAAATACGG
61 TTTCTAGTAC GTGGCAGGAA CGACTAGGTA AGCAGATTGA CGAATTAATA GAAAAACATT
121 AGTCAAATAC ATTTACAAAT GAACAGATAG TTGATATTAT ATTTAAGAAT TCTTCTTCAG
181 AGCCTAAGAT TAAAGCTTTC AATTGGCGAA AAGAAGTTGT ACAATATGTA TAAAGGTATG
241 TCAGTCACCG AATCAGATGA TCTGGCATTA TACTTGTAAA TTATCAGGAG GTTTTCATTA
配列番号11 グリセルアルデヒド-3-リン酸デヒドロゲナーゼプロモーター(天然)
1 ATCTCACGTG CGATCCATTA CACTAAGGGC GCGTCAACAA ATATTATACT ATCTTAAATA
61 AGAATGAATT GCAAGCATTA TTTGAAAATT TTAATTAAAA TAACGCTTAC ATCAGAAAAA
121 TGTTGTGATT GAATAGACAA TTTTTTTGAA GATGGTATCA TAAGTATCGT AGGAGTTGTA
181 TTATTGCTTA GACCTTACCA CTGCGTCACT TACAATGGTT GAGAGTTGCG ATGCTGATGT
241 AATGTGATAA ACTAAGCAAG TACACTAATT ATGTTTTTTC CTAAAGGAGG AATTTGCAGT
配列番号12 グルコース-6-リン酸デヒドロゲナーゼプロモーター(天然)
1 TTGTTTAAGA TATCTTTCAA AGCTGCGGAA TTTTTCCCAG CTTTTTTAGT TAGTTTTGTT
61 TTCATAAGCT ATAATTTTAA CCGATTCCAA ATTTCTTTTA AAAGTTTTTT TGATCTAGAC
121 CATTAATTGA TAAACGCTTA CCAAAGACTA ATCAACAAGC CATTTAGCGG TAGTGGTCCA
181 TTTTAACTTT CTAAGACATC TTCTCAGAAA ACGTTTCCTT TGATAGTGCA GATTGTGCTT
241 TAAGAGTATA TAATTGTCAC GGTATAAGAA TTTTCTGAAA TTTCAGAAGG AGTGAACATT
配列番号13 L-乳酸デヒドロゲナーゼプロモーター(天然)
1 CTCCTCTATT ATTATTCCTG ATCAATTTTA AATTAATCTC CCTAGATAGG TATATTTTAG
61 CACAGGTCAC CAACGTTCCA AAGTTTAATC TATGTTTAAA CTTTAATTTT CAAAAAAATG
121 CTATACTATG TTCACGATAC TTTAAGGAAA GGTGATTACA ATAGTGAGTC TCTTAATTGC
181 TATTCTTATC TGCTGGTTGC TATGGAAGAT TGGGGGTTTA ACGGTTAAGT TCATTGGTCT
241 AATCCTTCTT ATTCTATTAA TCGGGACATT AATTCATGTT TTACTTTGGC CAGCGATCCT
301 TTTAGCAGTT ATTATCTTAG GAGCAGGTTT ATTCACTAAC TAATTTATCT ATAAAATCTT
361 ATAGTAATTT TTCTGCGGAA TGTTATAATC ATTACTGTGA GAGAAATCTC AAATAATGTA
421 TACATAAGAT GAAAGGGAGA CTGTTTATT
配列番号14 tufプロモーター(天然)
1 ACAAATACGG TTTCTAGTAC GTGGCAGGAA CGACTAGGTA AGCAGATTGA CGAATTAATA
61 GAAAAACATT AGTCAAATAC ATTTACAAAT GAACAGATAG TTGATATTAT ATTTAAGAAT
121 TCTTCTTCAG AGCCTAAGAT TAAAGCTTTC AATTGGCGAA AAGAAGTTGT ACAATATGTA
181 TAAAGGTATG TCAGTCACCG AATCAGATGA TCTGGCATTA TACTTGTAAA TTATCAGGAG
241 GTTTTCATTA
配列番号15 Cタンパク質アルファ-抗原前駆体(天然)
1 MVSKNNHQFY QQKHAERKQR WGIRKLSVGV ASVLLGTTFM LYGNHAVLAD TVTSPSDDVT
61 RSTTTQGGNK DKVTEGTTEG TTSTPQTSGD STDKQANGQN VNQQVPTTDT EEATNHQDTP
121 QGQDTTQNTT NVDKKDTEVT PANDATTPTT QKITAKFTTA KFTTAKFTAA KFKVLAARPV
181 MKVAGTASLP ISNQDIKLDS QPMLTEIINK PTDNWVYNNL KWYQDTSTEK IKEILQNHTA
241 NDESGRYYFA GVANYNEHYH AIYLLARSNN LNDNSLYVTI LHTGLGKNIQ EAVVAPGESK
301 KVEYSGTTHT PIFTNYDGTS ASIDLDGIEK GDNIYGMVVG FAYGHNTGIK GDPASMGNGF
361 VMTPIPTKMT TTIHYIDQAT GDEIAVPKSF EGVAYQKYTI TGEAPTIDGY TLKKSPETTG
421 YISPYKVGES YDFRLDKHVV IKQTVIDAQG LVRVTAYYDG EVLNNTTRYL GNKLNVNDRM
481 SFISHGKWYT YINQITSTND GIVYYYAKDG SEDKSEVRVH YIDVTGSKNS IFVPGDGEEV
541 ATDKISGKLG ENYNYDVNLP TDYNLATNQA NTVNGTYTID HHDEYVYVVK KTSAELDPTV
601 PAKTKVDNPT SLTADEKKTI EDKIVEANKD KFPEGTGVTV ANDGKATITY PDKSVDTIEG
661 NQLVEEKTSA EKLDPTVPAK TKVDNPTSLT ADEKKTIEDK IVEANKDKFP EGTGVTVAND
721 GKATITYPDK SVDTIEGNQL VEEKTSAEKL DPTVPAKTKV DNPTSLTADE KKTIEDKIVE
781 ANKDKFPEGT GVTVANDGKA TITYPDKSVD TIEGNQLVEE KTSAEKLDPT VPAKTKVDNP
841 TSLTADEKKT IEDKIVEANK DKFPEGTGVT VANDGKATIT YPDKSVDTIE GNQLVEEKTS
901 AEKLDPTVPA KTKVDNPTSL TADEKKTIED KIVEANKDKF PEGTGVTVAN DGKATITYPD
961 KSVDTIEGNQ LVEEKTSAEK LDPTVPAKTK VDNPTSLTAD EKKTIEDKIV EANKDKFPEG
1021 TGVTVANDGK ATITYPDKSV DTIEGNQLVE EKTSAEKLDP TVPAKTKVDN PTSLTADEKK
1081 TIEDKIVEAN KDKFPEGTGV TVANDGKATI TYPDKSVDTI EGNQLVEEKT SAEKLDPTVP
1141 AKTKVDNPTS LTADEKKTIE DKIVEANKDK FPEGTGVTVA NDGKATITYP DKSVDTIEGN
1201 QLVEEKTSAE KLDPTVPAKT KVDNPTSLTA DEKKTIEDKI VEANKDKFPE GTGVTVANDG
1261 KATITYPDKS VDTIEGNQLV EEKTSAEKLD PTVPAKTKVD NPTSLTADEK KTIEDKIVEA
1321 NKDKFPEGTG VTVANDGKAT ITYPDKSVDT IEGNQLVEEK TSAEKLDPTV PAKTKVDNPT
1381 SLTADEKKTI EDKIVEANKD KFPEGTGVTV ANDGKATITY PDKSVDTIEG NQLVEEKTSA
1441 EKLDPTVPAK TKVDNPTSLT ADEKKTIEDK IVEANKDKFP EGTGVTVAND GKATITYPDK
1501 SVDTIEGNQL VEEKTSAEKL DPTVPAKTKV DNPTSLTADE KKTIEDKIVE ANKDKFPEGT
1561 GVTVANDGKA TITYPDKSVD TIEGNQLVEE KTSAEKLDPT VPAKTKVDNP TSLTADEKKT
1621 IEDKIVEANK DKFPEGTGVT VANDGKATIT YPDKSVDTIE GNQLVEEKTS AEKLDPTVPA
1681 KTKVDNPTSL TADEKKTIED KIVEANKDKF PEGTGVTVAN DGKATITYPD KSVDTIEGNQ
1741 LVEEKTSAEK LDPTVPAKTK VDNPTSLTAD EKKTIEDKIV EANKDKFPEG TGVTVANDGK
1801 ATITYPDKSV DTIEGNQLVE EKTSAEKLDP TVPAKTKVDN PTSLTADEKK TIEDKIVEAN
1861 KDKFPEGTGV TVANDGKATI TYPDKSVDTI EGNQLVEEKT SAEKLDPTVP AKTKVDNPTS
1921 LTADEKKTIE DKIVEANKDK FPEGTGVTVA NDGKATITYP DKSVDTIEGN QLVEEKTSAE
1981 KLDPTVPAKT KVDNPTSLTA DEKKTIEDKI VEANKDKFPE GTGVTVANDG KATITYPDKS
2041 VDTIEGNQLV EEKTSAEKLD PTVPAKTKVD NPTSLTADEK KTIEDKIVEA NKDKFPEGTG
2101 VTVANDGKAT ITYPDKSVDT IEGNQLVEEK TSAEKLDPTV PAKTKVDNPT SLTADEKKTI
2161 EDKIVEANKD KFPEGTGVTV ANDGKATITY PDKSVDTIEG NQLVEEKTSA EKLDPTVPAK
2221 TKVDDPTKLT NDEKKEVEDN IRDHNTGLPE GTKIAVGDNG DTTITYPDKS VDTIEGNQLV
2281 EEKTSAEKLD PTVPAKTKVD DPTKLTNDEK KEVEDNIRDH NTGLPEGTKI AVGDNGDTTI
2341 TYPDNSVDTI PGDKVVEGKS DAAKNEPKVP GDKVKVDDPN KLTEDEKSEV VKAVEDANKD
2401 ENGKSTLPEG SKVTVGDNGD VTVTYPDGSK DTIPGDKVVE GKGTEGQTDA DKNEPKVPGD
2461 KVKVDDPNKL TEDEKSEVVK AVEDANKDEN GKSTLPEGSK VTVGDNGDVT VTYPDGSKDT
2521 IPGDKVVEGK GTEGQTDADK NEPKVPGDKV KVDDPNKLTE DEKSEVVKAV EDANKDENGK
2581 STLPEGSKVT VGDNGDVTVT YPDGSKDTIP GDKVVEGRGT EGQTDADKNE PKVPGDKVKV
2641 DDPTKLTEDE KSDVEQAIKD ANKDENGKST LPEGSKVTVG DNDDVTVTYP DGSKDTIPGD
2701 KVVEGKGTEG QTDADKNEPK VPGDKVKVDD PNKLMEDEKS DVEQAIKDAN KDENGKSTLP
2761 EGSKVTVSDN GDVTITYPDG SKDTIPGDQV IEGKSDADKN TPNVPGGDKV KVDDPTKLTD
2821 NEKNAVKDKV DEANSNLPDG TKVTVGDDGT TTITYPDGST NTISGHDLVT GKTDADKYPL
2881 NPGQAVNVVD PNHLTQAEQD QVKEAIQTTN PTAPIATITV DTAGNVQVTF ADGSTTTLQA
2941 NLHKHVTEAT TGSAIKPGVG TNGGQTKGAT STNQTATKQQ AQQHLPQTGD QPATWAMLSG
3001 LGVAFLGLLG LKKKRED
配列番号16 アラビノガラクタンエンド-1,4-ベータ-ガラクトシダーゼ(天然)
1 MEIKKHFKLY KDGKKWCCAA IATTVLGIGL AIGSPSVLAD ADTITSTSDA NNSLVKNDNT
61 SDTDSNSEST FTDTNKNSTN EKEINENKNI DSSQQINQEQ TKSNNSEEQT TPVNVKAENT
121 DIKDSIPEKS TPNSFKEING STYYYGENGD LYRNQFYNNW GRTYYFQANG ARLDNGFYNN
181 WGRTYYFGSD GARWDNRFYN NWGRTYYFQN DGSRLDNSFY NNWGRTYYFG VDGARWDNRY
241 MVKWGRAYYF GNDGALLQNQ LKSINGINYW INNEGIIPLK NQFLTANENQ LFYFDGNGSL
301 VVNKFYHNWG HTYYFGSDGA RYTDQFLNRD GKVYYFDNQG IMYQDQYYKN WGHTYYFGSD
361 GARYTDQFLN RDGKVYYFDN QGIMYQDQYY KNWGHTYYFG SDGARYTDQF LNRDGKVYYF
421 DNQGIMYQDQ YYKNWGHTYY FGSDGARYTD QFLNRDGKVY YFDNQGIMVT NQVRVIDGKG
481 YEFNDNGEAT ETSDMGQTRD TVAKEVAQAL TNQGIKGVKY DWRNTNNDYQ ELALHDIAQE
541 VAQGDTNPDK NVIEKKLQAN NLLSGKVLVV YSTDFTNDDP QKITNTFMNS YDFTNADNSV
601 LGVGADLNKN KLVIILFKPG EKAEQPQATS TISASISDIF KKAGVNVDVD NGLTKGSVVN
661 SADLGNALTN GTAELLKGDK GTIISQEVLK AIFAAFAGNT SAVEGTKNYY NGNDAYHYEF
721 WLEGQSADDK LNNFLALNKG AKYGDQLKVN YTATLVFGQE TGTNSNESKV PASERTDEQL
781 DLAYKTGTDT GLRYDSVKVE KIPGMTDDMV RGVDVSSYQA LINAGVKFYD FNGQESNLFK
841 ILKDSGVNWV RLRVWNDPYN AQGQPYAGGD NNEENLIKMA KEASDNGLKL LIDFQYSDFW
901 TDPAQQILPK AWRNLSHGEM SQEVYLYTSK ILNDLQKAGA SVKMVQIGNE ITNGAFGLYT
961 GRNGGGNWAS LWETSDGDQV AKYIQAGSSA VRRIDPTIKV AIQLETPEIN KYRGIMNVLK
1021 KNNVDYDYLG TSYYPFWSTT QGNGWYDNVD LGYGANTPVN LEAIEKMAWN EFGKRTVILE
1081 SGWLNNTNDA DGTHNSVGEN NETTNIDRYS ADPQGQVDEI EDMYNAIIAQ KGLGAFYWEP
1141 AWIPVKAGWN NWQYNKLMSN IYGSGWASQY AKGYAPDSVL YYDGKEAWGG SSWDNISLFD
1201 DHGHPLQSLN VYNGMLNGYE SPKNVKSSLS TQLVKIWNET DVIPNDGLTE GTKLSTDLFG
1261 TTQLSGNDGQ SIGNAELTKL AGRLKDGISS KVYTAANGAR YHYIYWLEGG NNKVNTFVSA
1321 NKDAKYGQPL IANYSATVVV DSEPGTQVAT SPLQIKISQV WNTVNNEEIK IDNPLKQGDL
1381 ITDKSDNAFS GILNSKDIKE ALTGEKGKDV SESTVNDVKS LLPKEVKGSK TYTTADGNQY
1441 YYDFWLASVE TSNVNYGEPI IVNYTASLKW LG
配列番号17 染色体分離タンパク質(Chromosome segregation protein)(天然)
1 MEKTMKKKAL VATTAVAGIT LVGEVTTVHA ADNVQQPVNE QNVNQSSQEE KQAAQNLQNA
61 QSDVNTATEA NSNAQDNLAS ANNNLSNAKK AVSDQAAKVA DATKAQSDAS TKVDNDNKVV
121 ADAQQKADQA TPANIENAKQ AIEGQNKVID QDNENIKYSN TDQDKAQNTL NNAQSNEDKA
181 NATLSNKKSS QASAQNNVKQ AEDALNGTHL VEAQNAFNQA QSNVENAQSK YDQANNQLSD
241 AQKKVTTNQN DLTAKNKALD NINNQVDTDQ NNVNSNQATA DSASSATQVA QNAVDQTKQS
301 LDKVIEELNG FSENTIKVPA GAQEAYEAFI DAVDNNADQS QLDSLAKKMY DTLHQGQGTN
361 GINHFNSSKY DQNQLVDVDH LTTDQLNELT QFAADMINSA RKAWGSDKNA GTLIPTQGVS
421 EMAQQIAKGY VSDNWHISQG HDVKRVTAAA GLIGLNDAGQ FYEDASEGYV HAWPWEKDSY
481 TMDNLKEAVY DSILGMLFAD DNSGNGHMTD LLGLHVNRKE DHQYFGLSTN MCPGSYMGQL
541 HFIIVENDPA YIKDPQTFNA KGGTTKIEYI DPKVQLNQQK DILTTTLSTQ QADLATKQDA
601 LNKANQNLAN AKKQLSEDQD LQTVAQQNRD SAQKALNDAT AKVSNLQATV NSLSQDLNSA
661 KATLDQAKKT LESYTADHKA KLDNYNNAKA ALDDANKAVA EAQSAVDTAV NETKIAQNNL
721 DQKKQAVTDA QNKLANDQEY LATLKQNLAD LQNAPQNLQK AKDQLAKDQI ALDNANKDLQ
781 NQKDSLDELN KKLEDAQVKV NEAQSAANVT KATLDQAQAK LSDAEATWKE LHNDAHRYGN
841 VVKVTPITME AGTSLPDPVI ENGFTVNTGT NQLFVSLAAI DSSNNNIPQG TKASWANRSK
901 ALTDSQNAGS YSEDILITFP DNSTVTVPVD LTVTAKKITE DQKATEGGYH IVNGSVVDKQ
961 NNLVSGWTVK NGQMVDPEGN VIKTTMSTAQ GVTIEKNNSK SGNTKTNMIQ TSLTIANNKA
1021 TTNKDNQLPQ TGNYNNNTKV LGLAGIALAS ALTMFGYKKR QHN
配列番号18 D-ガンマ-グルタミル-メソ-ジアミノピメリン酸エンドペプチダーゼCwls(天然)
1 MKSTTKKILA SSLGVAGAMA MGTVTAKADT TVTVNAGDSL NGIAQKYNVS ADDIATANHL
61 QNKELIFVGQ KLTIPTKDKN ETPANNAEKK DQASKNSQSL QDSVNKAMSY LGTPYVWGGN
121 KPGGFDCSGL VQYCYGIPQR TTYEQQALGP HIHDNVLNAP YGALVFYGSD DAPYHVAISL
181 GDGRIIQAPN ENETVKITDQ QYFPGNYYVV MH
配列番号19 N-アセチルムラモイル-L-アラニンアミダーゼsle1前駆体(天然)
1 ATGCGTAATC AATTCATCGA TGTTTCAAGT TATCAACCAG ATACTGTTGC CTTTTTCCAA
61 GCTGCTAAAG CTCAGGGTGC ATTAGGGGTC GTTGTTAAGT TAACGGAAGG GTCCGAAGAT
121 GGTTCGGCTT ATGTTAATCC ACGTGCGGCC GCTCAAATTC GTAATGCCTT AGCGGTTGGC
181 TTGCGCGTTT CCTGTTACCA CTTTGCTCGT TATACATCAG TGACTGATGC ACAAAATGAA
241 GCTCGATTCT TCGTTAAAAT CGCTAAGCAA TTTGGTATGT ATGACGATAC TTTGATGATT
301 GATGATGCGG AAGTTCATTC AACTGCAGAT TATCAATCAG TATCCTTAGC CTTTCTTCAA
361 GAAGTAGAAG CTCTTGGTTA CAAGAATACT GGGATTTACT CCATGAAGTC CTTCTTCACT
421 GGCGGTATTC TTAATTCACA TGGCTTTGAT TCCCGGAAGA TTTGGATTGC TGGCTATGGT
481 GTGACTGAAC TGGGGATTGA TAATGCAAGT GCTTGGCAAT ATTCTGATCA TAGCATCATG
541 GGAATTGATA CTAGTTATGA CTTTGACGGT GCCTTTACGA CTGGTTTAGT ATCAGGCAAT
601 GTTCCGCAAG CTGTTATTCC AGCACCACAG CCGGTTCAAC ATATTGGTCA CCCAGCTACT
661 GGAACCTACA TTGTTCAGCC GGGCGATACA TTGAGTGGAA TTGCAGAAAA ATACGGGACT
721 ACTTATCAGA ACCTAGCAGC AATCAATGGT ATTGGTAATC CAAACCAGAT CAATGTCGGC
781 CAAGTCCTCA AAGTCACCGG AAAAGTATCA AACGAAAATA CTTACTTTGT TCAATCAGGC
841 GATACGTTAT CCGGAATTGC CACCAAATTC GGCACCACTG TCTCAGACCT CGTAAGCCGT
901 AATCACATTA CTAACCCGAA TGTGATCTAC GTTGGGCAAA AACTCTACTT AGCCGGCAAC
961 GGACAATCCA ATGCTTATAC TGTCCAAGCA GGGGACACAC TAAGCGGAAT TGCGGCTAAG
1021 TTTGGCAAGA CCTGGCAAGC ATTAGCTCAA AAGAATGGCA TCGCAAATCC TAATATGATT
1081 TTCATTGGTC AAACAATTCA GATTTAA
配列番号20 ペプチダーゼファミリーM23(天然)
1 GTGTACCGAA TTATTGGTTA TAATGAACCA ACAGATAAAG CAGGATTTAT TGTACTGGAT
61 CCCCGAGTTA ATCGTCATAT TAGTTCGGGA AAACTCACGC TTAAAGAATC TAATATTGAT
121 GATTTGACTA TTACGGTTAA TCAAGCAAGT CCATTATGGG ACAACGTAAG GCCTTATCAT
181 ACTCATGTTA ACGTTTATGA TGATAATGAA CTTATTTTTC GTGGACGAGC TATCAAACCT
241 AAAAAGTCGA TGGAAGAAAG CGGACAATTC ATTCGTGAAT ATGTTTTTGA AGATATTGAA
301 GCATATCTCA TGGATAGCAC CCAAAGATTT TATGAAGGTG TTGGTCAAAC GCCCAAAGAA
361 TTTTTACAAA CTTTAATCGA TGTTCATAAT TCACAGGTTC CTGACTATAA AAAGTTTCAA
421 GTCCGGAATG TAAATGTCAC TAATAATAAG GATGACCAAT ATCGACAAAT TGATTATCCC
481 AAAACTAGCG ATGCTATTAA TGATAAATTA GTTAAATCTC TTGGTGGTTA TATTGTGACT
541 ACTTACAACG CTAACGGAAT AAACTACATT GACTACTTAA CGGATATTGG GGTTGATCAT
601 AAAGATGATA CTCCTATTCA GTTAGCTAAA AATATGAAGT CTGCAAGTAT GCAAATTGAT
661 CCTACTAAGG TGATTACAAG ACTGATTCCA CTGGGAAAGA CACTAGAACC ATCAAAAGTT
721 GATGTAAGTG ATGATGATGG AGAGGGCGGT TCTGGATCAT TAGATAGCCC TGAAGAATTT
781 TGTAAATCAG AAATTAATGC TACTTGGGGT AGTGATATTA ATAATATGAA ACAAGATTTT
841 GCCGCTCGTT CTTCGAGAGT TCGGGCTTGG GGAGTGGACG TTAATCGTTT ATATGATGTG
901 GTGAAAAATG CTGGAGTAAG TCCTGAATGG TTCTTTGCTT ATGAACTTCA AGAACAAGGA
961 ACTTACTATG GATGGCTTAA CCATACTTAT CGACACGGTG ATGCGTATAG TGATGCGCAA
1021 TCTGTTTGTG AGTGGATTAA AAATTGTTCA AATAGTAATT CCATTAATCC AGCATGGAGC
1081 GCACCGGAAG GATCAATGGC GCCGAATCAA GCATTAGCGG ATAAATGGAA TCAAGAGTTT
1141 GGAAAAGGTA CTATTGGCCG CGTTTATTTA CAAGGGACTG CCGCTGCTGT TTGGGATTTA
1201 GCTGGTCAAA CGCCTAATCC AGCTATTGGA AAGCCAATTA GTGGATGCAT TTCTTGTATT
1261 AAACGTTGGG GTGGTCATTC TAATGCAGCT GGTGGTACAT GGGGATGGCC TTTTCCTGAT
1321 GTTGGGGAAG GTCATTTTTC TCAAGTTCAG AGTTTCGGAA ATGATGGCGG ATATCGTCAA
1381 AATAGTTATC ACGATGGTGT GGATTTTGGA TCAATAGATC ATCCTGGTAG AGAAGTGCAT
1441 TGTATTCATG GTGGAACGGT AACTATCAAA TCAGCTATGG GTGGCTTAGG TAATTTTGTG
1501 GTTATTCATA CGCCGGAAGG ATTCAATATC GTTTATCAAG AAGCTTTTAG TTCTCCCTCT
1561 AATATTATTG TTAGTGTTGG GCAAAAAGTA AAAACTGGTG ATGTAATTGG ATATCGTGAT
1621 ACAGACCATG TTCATATTGG CGTAACTAAG CAAGATTTTT ATCAAGCAGT TCGAAATTCT
1681 TTTTCTCCTG CAGGTGGTTG GCTAGATCCA GTAAAACTAA TTAAAGAAGG TGGCGATGGG
1741 TCTAAACCAC AAGAAGGAAA GAAAGATCAA ACTGTTGATA ATAGTAATGC TGCACGTCCT
1801 AAATTAACCA TTACTACTGT CAATAACGGT AGAGACTATA TTGATATTCC TGATTTACAA
1861 AAAGAATTCG GTATTATTGA GGGAACTGTT GAATTTGATA ATGTAGATGA TCCGAATGTT
1921 TTAATGCAAC AAGCTCAAAC ATGGATAAAG GCTCAAAGAA TACCTCAAAG TTGGGAAGTT
1981 ACAGCTTTAG AATTACATAT GACAAACTTC AAATCTTTTA AGGTTGCTGA TAGGTACATG
2041 TTTATTAATC CAAATGTTGC AAAACCCCAA TTATTACGAA TTACTCAAAA AGAAATTGAT
2101 TTACTAAAGC CCCATGCGTC TTCATTAACG ATTGGTGATA AGACGATGGG GCTTACTGAT
2161 TATCAGTTAG AAAATCAAGT CAATTTTCAA CAATTTAAGG AAATTCGAGT GATGGTTAAT
2221 CAGGTTGTCC AAACCCAAGA GCAATCTGCT AATAACAATA ATAAGGTTAT GCAAAATTTT
2281 GCTAGTAGTG CTGATCTTGC ACAAATGAGA CAGGATCTAA GAAATCTTCA AGATGATAAC
2341 GATCGTGCTC GCAAAGGAAT GGTTTCCTTA GAAGAATTCA ATAAACTAAA GGAACAAGTA
2401 GAAAAACTAA CAACAGGAGG CGATGATAAT GGCAAGTGA
配列番号21 染色体分配タンパク質Smc(天然)
1 MNKANQKVAD DTTAVNNKQT DVNNAAEAKK NADEALKNAN DAQTSAQKNK DAKQAIADEA
61 SVALADANTA VKDAQAKVDA INDKLANFNT ITLPAGYKDD LIAYYNYFGN SNYNQDEANN
121 LAQDLLKYRD QAMSQNKFKD NLSDDRVVDI DNLNSTDRAE LSQFVASLIN QVRTQMGTNL
181 VISSPAADDY AEQVSQNYNK DNWNSADNGK HDQSALNNAT DQLNISWNGE NMGLDQSIFT
241 TDYTVLTDGT KLPTGNKQTI NDLKHLIYDD FISMMFDDAD SAWGHATNFA GIDNFAAEKQ
301 AVGFSLDKFY NTHYDLVEAN QKVEENSYTL PSINALTQKL ADAKDDLSIK QTDQASKQKA
361 NDDAQNALSS ANQVLVAAQN DVKDKTATAQ EANDNLTTAQ NDLATLQNQL SADQANQKQA
421 QTTFDSFDAD LATKQANLQK ATDSLKAEQG RLAIAQADLD NANKALSDAN NNLAQKKQVV
481 ENDNETLKVD NDKLVQLQNN LSDLQNAPKL LAAAKEQVAT AQKALADAQE AYNVANDKLT
541 SLKQTAAGTT TNVSKAQQAL AEAKNNEDAA KEVLDQAQQA LTELRQKEAL AKQVAEEQAK
601 LAAEKEAKDN GYHIENNQVV DAKGNSVNGW TVKGNQIVSP TNATVDPAVS VTTNVNVDSK
661 GQVQPQTSVT ANSVKTVAAT ESANPVATTT VQTREQYKQQ LKSNNQLPQT GNNDSAVLSL
721 AGVALAAMLS LFGIKKREY
配列番号22 Cwlsエンドペプチダーゼプロモーター(天然)
1 AAATTAAAAG GCTGGATTTT TTCGGCCTTT TTTTAGTGCA AATAATTATT TTTTACGTAT
61 TTATATTATA GGGCTAATCA CTAAACTAAT AATTAGTGGT TGAAGCGCTG AAAATTTTCT
121 GCTATTTTAT TAATAGTTTG ATAATAAAAT AATGATATTT AATATAAAGA GGGATAAACG
181 AAATA
配列番号23 染色体分離タンパク質(Chromosome segregation protein)プロモーター(天然)
1 GAAGTACAAA GTTACTTTAA CTATAATGAA AAACAAGACA ATATAAAGAA AACAACATAT
61 AAGGTTCAGT TCATAACTGA TTAGATTTAT AATAAATATT GTAAATCGGA CAAAAATAAA
121 TTAATTTTCA ATTAATTCAA AAAAACCATA TTTTTTTCGT TTTGGCATAT TTGGATTTGC
181 TACACTAAAG ATGATCAAGA AAGGGGAAAA GATAATCTTC AATCTTGTGT ACTTAGTTTG
241 TTAATTAATT TATAAATTTA GGGAGGAAAC CTATC
配列番号24 染色体分配タンパク質Smcプロモーター(天然)
1 GCAATGCACA AGATGCTGAA ACAAAGGCAC AACAAAATGC AGATCAAGCT TCACCAGCTA
61 ATATTCAAAA GGCACAAGAT GCTATTGCTA ATCAAGAAAC TCAAATTAGT AAAGACACCG
121 ATGCTATTAA TGACGCTAAC AAAGCCGTTA GCGATGCACA AAGCACAGTT GATGCAGCGC
181 AAAAAAAGTT AATGATGCAA CTACTGCTCG TGACAATCAA CAAAAGAATG TTGATACTGC
241 TAGTGATGCA GTTAAGAATG CTCAAGCTAT TCTTGACAAC AGTGATCAGG CTAAAAAGGA
301 AGCCCAAGAT GCT
配列番号25 ラクトバチルス・ロイテリ3630 F1 16S
1 GCCGCGGGTG CCTATACATG CAGTCGTACG CACTGGCCCA ACTGATTGAT GGTGCTTGCA
61 CCTGATTGAC GATGGATCAC CAGTGAGTGG CGGACGGGTG AGTAACACGT AGGTAACCTG
121 CCCCGGAGCG GGGGATAACA TTTGGAAACA GATGCTAATA CCGCATAACA ACAAAAGCCA
181 CATGGCTTTT GTTTGAAAGA TGGCTTTGGC TATCACTCTG GGATGGACCT GCGGTGCATT
241 AGCTAGTTGG TAAGGTAACG GCTTACCAAG GCGATGATGC ATAGCCGAGT TGAGAGACTG
301 ATCGGCCACA ATGGAACTGA GACACGGTCC ATACTCCTAC GGGAGGCAGC AGTAGGGAAT
361 CTTCCACAAT GGGCGCAAGC CTGATGGAGC AACACCGCGT GAGTGAAGAA GGGTTTCGGC
421 TCGTAAAGCT CTGTTGTTGG AGAAGAACGT GCGTGAGAGT AACTGTTCAC GCAGTGACGG
481 TATCCAACCA GAAAGTCACG GCTAACTACG CCCCCCACCA GCCCCAA
配列番号26 ラクトバチルス・ロイテリ3632 F1 16S
1 TGCTGGGGTT TGCCTATACA TGCAGTCGTA CGCACTGGCC CAACTGATTG ATGGTGCTTG
61 CACCTGATTG ACGATGGATC ACCAGTGAGT GGCGGACGGG TGAGTAACAC GTAGGTAACC
121 TGCCCCGGAG CGGGGGATAA CATTTGGAAA CAGATGCTAA TACCGCATAA CAACAAAAGC
181 CACATGGCTT TTGTTTGAAA GATGGCTTTG GCTATCACTC TGGGATGGAC CTGCGGTGCA
241 TTAGCTAGTT GGTAAGGTAA CGGCTTACCA AGGCGATGAT GCATAGCCGA GTTGAGAGAC
301 TGATCGGCCA CAATGGAACT GAGACACGGT CCATACTCCT ACGGGAGGCA GCAGTAGGGA
361 ATCTTCCACA ATGGGCGCAA GCCTGATGGA GCAACACCGC GTGAGTGAAG AAGGGTTTCG
421 GCTCGTAAAG CTCTGTTGTT GGAGAAGAAC GTGCGTGAGA GTAACTGTTC ACGCAGTGAC
481 GGTATCCAAC CAGAAAGTCA CGACTAACTA CGCCCCACAC CCCAGCCGCA A
配列番号27 ラクトバチルス・ロイテリ3630_00184
1 ATGGATATGA AAATAAAAAA AGAACCACCA CAACAAGTAA AATTAGTTGA AGTAATTCAG
61 GTTATAACCT CTCGTGGAGC TGGAACAAAG GAGGATCCGA TAAGAAAGAT TATTCAGTAT
121 TGGAGCAAAG AAGGCACATT ATTAGCAGAA AGTTTTGGAA ACTAA
配列番号28 ラクトバチルス・ロイテリ3630_00491
1 ATGGCTGGTA TCAAAAGTAT CGCAAAAGCG GTAATGACCC AGAATCACTT CGTGATCGCC
61 GAGGCAAAGC TAAGCCAGAA GAGAAGTGGA CGGAAGTTGA CCGACTCAAG GCAGAAAATC
121 GCTTATTAA
配列番号29 ラクトバチルス・ロイテリ3630_00497
1 ATGGCTAAAT ACACTGTTGA ATTAAGTGAA GAAGATATCC AAATGATCAA GGATTGTCAT
61 TCAAAGAATC CTTCTATCAT GAAGGCAATG AACGACGCTA AAAAAGTTGA AGATTAA
配列番号30 ラクトバチルス・ロイテリ3630_00533
1 GTGGATGCGG ATTCGCTGGC ACTCGTTGAT GCACTTTCAC TTGCGCTCGT TGATGCCGAT
61 TCACTGGCAC TCGTTGATGC ACTTTCGCTA GCACTAGTAG AAGCTGACTC ACTTGCACTT
121 GTCGATGCCG ATTCGCTTGC ACTTGTCGAT GCTGATTCGC TTGCGCTCGT TGAGGCTGAT
181 TCGCTAGCAC TAGTAGAAGC TGATTCACTG GCACTCGTTG AGGCACTTTC ACTTGCGCTT
241 GTTGAAGCCG ACTCACTTGC GCTCGTTGAT GCACTTTCGC TGGCACTTGT CGATGCCGAT
301 TCACTTACGC TCGTTGAGGC CGATTCGCTG ACACTCGTTG ATGCACTTTC ACTTACGCTC
361 GTTGAGGCCG ATTCGCTGAC ACTCGTTGAT GCACTTTCAC TTACGCTCGT TGAGGCCGAT
421 TCGCTGACAC TCGTTGATGC ACTTTCGCTG GCACTTGTCG AGGCACTTTC ACTTACGCTC
481 GTTGAGGCCG ATTCACTTAC GCTCGTTGAG GCCGATTCAC TTGCGCTTGT GGATGCGGAC
541 TCACTTGCAC TCGTTGAGGC ACTTTCACTT GCACTTGTCG ATGCAGATTC GCTGGCACTC
601 GTTGATGCAC TTTCACTTGC ACTCGTTGAT GCACTTTCAC TTGCACTTGT CGATGCGGAT
661 TCACTTGCAC TTGTTGAAGC GGATTCGCTA GCACTTGTCG ATGCGGATTC ACTTGCGCTT
721 GTTGAAGCGG ATTCGCTGGC GCTTGTTGAA GCCGACTCAC TTGCACTCGT TGAGGCTGAT
781 TCACTTGCAC TCGTTGAGGC ACTTTCGCTG GCGCTCGTTG ATGCAGATTC GCTGGCACTC
841 GTTGAGGCCG ATTCGCTGGC GCTTGTTGAG GCCGATTCGC TTGCACTTGT CGATGCTGAT
901 TCACTTGCAC TGGTTGAAGC AGATTCGCTG GCACTCGTTG AGGCACTTTC GCTGGCACTC
961 GTTGAGGCCG ATTCACTTGC GCTTGTTGAA GCTGATTCAC TTGCACTTGT CGATGCTGAT
1021 TCACTTGCGC TAGTAGATGC CGATTCGCTG GCACTCGTTG AAGCAGATTC ACTTGCGCTT
1081 GTTGAAGCCG ATTCACTTGC GCTTGTTGAA GCCGACTCAC TTGCACTCGT TGAGGCACTT
1141 TCGCTGGCGC TCGTTGAAGC AGATTCGCTG GCACTCGTTG AAGCAGATTC GCTGGCGCTT
1201 GTTGAGGCCG ATTCGCTTGC ACTTGTCGAT GCTGATTCAC TTGCACTGGT TGAAGCAGAT
1261 TCGCTGGCAC TCGTTGAGGC ACTTTCGCTG GCACTCGTTG AGGCCGATTC ACTTGCGCTT
1321 GTTGAAGCTG ATTCACTTGC ACTTGTCGAT GCTGATTCAC TTGCGCTAGT AGATGCCGAT
1381 TCGCTGGCAC TAGTAGAAGC AGATTCACTT GCGCTTGTTG AAGCCGATTC ACTTGCGCTT
1441 GTTGAAGCCG ACTCACTTGC ACTCGTTGAT GCCGATTCAC TTGCACTTGT GGATGCGGAC
1501 TCACTTGCAC TCGTTGATGC ACTTTCACTT GCACTTGTGG ATGCGGATTC GCTGGCACTC
1561 GTTGATGCAC TTTCACTTGC GCTCGTTGAT GCCGATTCAC TGGCACTCGT TGATGCACTT
1621 TCGCTAGCAC TAGTAGAAGC TGACTCACTT GCACTTGTCG ATGCCGATTC GCTTGCACTT
1681 GTCGATGCTG ATTCGCTTGC GCTCGTTGAG GCTGATTCGC TAGCACTAGT AGAAGCTGAT
1741 TCACTGGCAC TCGTTGAGGC ACTTTCACTT GCGCTTGTTG AAGCCGACTC ACTTGCGCTC
1801 GTTGATGCCG ATTCACTGGC ACTCGTTGAG GCACTTTCAC TTGCGCTTGT TGAAGCCGAC
1861 TCACTTGCGC TCGTTGATGC ACTTTCGCTG GCACTTGTCG ATGCCGATTC ACTTGCGCTT
1921 GTGGATGCGG ACTCACTTGC ACTCGTTGAA GCCGATTGGC TTGCACTAGT AGAAGCTGAT
1981 TCACTGGCGC TCGTTGAGGC TGATTCGCTG GCGCTCGTTG AGGCTGATTC ACTGGCACTC
2041 GTTGAGGCCG ATTCGCTGGC GCTCGTTGAT GCAGATTCGC TGGCACTAGT AGAAGCTGAT
2101 TCACTGGCGC TCGTTGATGC CGATTCACTT GCACTTGTCG ATGCGGACTC ACTTGCACTC
2161 GTTGATGCAC TTTCGCTTGC ACTTGTGGAT GCGGATTCGC TGGCACTCGT TGATGCACTT
2221 TCGCTAGCAC TTGTCGATGC CGATTCACTT GCACTCGTTG ATGCACTTTC GCTAGCACTC
2281 GTTGATGCAC TTTCACTTGC ACTTGTGGAT GCGGATTCGC TGGCACTTGT TGATGCGGAC
2341 TCACTTGCAC TTGTTGAAGC CGATTCACTG GCGCTCGTTG ATGCCGATTC ACTTGCACTT
2401 GTCGATGCCG ATTCACTGGC GCTTGTTGAT GCGGACTCAC TTGCACTCGT TGATGCACTT
2461 TCACTTGCAC TTGTGGATGC GGATTCGCTG GCACTAGTAG AAGCTGACTC ACTTGCACTT
2521 GTCGATGCCG ATTCACTGGC ACTCGTTGAA GCACTTTCAC TTGCGCTTGT TGATGCGGAC
2581 TCACTTGCAC TCGTTGAAGC CGATTCGCTA GCACTTGTCG AAGCTGATTC ACTGGCGCTC
2641 GTTGATGCTG ATTCACTGGC GCTTGTTGAA GCCGACTCAC TTGCGCTCGT TGATGCACTT
2701 TCACTTGCGC TCGTTGATGC CGATTCACTA GCACTAGTAG AAGCTGATTC ACTGGCGCTT
2761 GTTGATGCAG ATTCGCTGGC ACTTGTCGAT GCCGATTCGC TAGCACTAGT AGAAGCTGAT
2821 TCACTGGCGC TTGTTGATGC AGATTCGCTG GCACTTGTCG ATGCCGATTC GCTAGCACTA
2881 GTAGAAGCTG ATTCACTTGC ACTTGTCGAT GCCGATTCAC TGGCGCTCGT TGATGCCGAT
2941 TCGCTGGCAC TAGTAGAAGC TGACTCACTT GCACTTGTCG ATGCCGATTC ACTGGCACTC
3001 GTTGATGCAC TTTCGCTAGC ACTTGTAGAT GCGGATTCAC TTGCACTCGT TGATGCACTT
3061 TCACTGGCAC TCGTTGATGC ACTTTCGCTA GCACTCGTTG AAGCACTTTC ACTTGCGCTT
3121 GTTGATGCGG ATTCGCTGGC ACTCGTTGAT GCACTTTCAC TTGCGCTCGT TGATGCCGAT
3181 TCACTTGCGC TTGTGGATGC GGACTCACTT GCACTCGTTG ATGCACTTTC GCTTGCACTT
3241 GTGGATGCGG ATTCGCTGGC ACTAGTAGAA GCAGATTCAC TTGCGCTCGT TGATGCCGAT
3301 TCACTTGCGC TTGTGGATGC GGACTCACTT GCACTCGTTG ATGCACTTTC ACTTGCACTT
3361 GTGGATGCGG ATTCGCTGGC ACTAGTAGAA GCTGACTCAC TTGCACTCGT TGAAGCACTT
3421 TCACTTGCGC TTGTGGATGC GGACTCACTT GCACTTGTCG ATGCTGATTC GCTAGCACTA
3481 GTAGAAGCTG ATTCACTTGC ACTCGTTGAT GCACTTTCAC TTGCGCTTGT TGAAGCCGAC
3541 TCACTTGCGC TCGTTGATGC CGATTCACTT GCACTCGTTG AGGCACTTTC ACTTGCGCTT
3601 GTTGAAGCCG ACTCACTTGC GCTCGTTGAT GCACTTTCGC TGGCACTTGT CGATGCCGAT
3661 TCGCTGGCAC TAGTAGATGC GGACTCACTT GCGCTCGTTG AAGCCGATTG GCTTGCACTA
3721 GTAGAAGCTG ATTCACTGGC GCTCGTTGAG GCTGATTCAC TGGTACTCGT TGATGCACTT
3781 TCGCTAGCAC TCGTTGAAGC ACTTTCACTT GCGCTTGTGG ATGCGGACTC ACTTGCACTA
3841 GTAGAAGCAG ATTCACTTGC GCTCGTTGAT GCCGATTCAC TTGCACTTGT CGATGCCGAT
3901 TCACTTGCGC TTGTGGATGC GGACTCACTT GCACTCGTTG ATGCACTTTC GCTTGCACTT
3961 GTGGATGCGG ATTCGCTGGC ACTAGTAGAA GCAGATTCAC TGGCGCTCGT TGATGCCGAT
4021 TCACTTGCAC TTGTCGATGC CGATTCACTT GCACTCGTTG ATGCACTTTC ACTGGCACTC
4081 GTTGATGCAC TTTCGCTAGC ACTCGTTGAA GCACTTTCAC TTGCGCTTGT TGATGCGGAC
4141 TCACTTGCAC TTGTTGAAGC CGATTCACTG GCGCTCGTTG ATGCACTTTC ACTTGTGCTT
4201 GTTGAAGCCG ACTCACTTGC GCTCGTTGAT GCACTTTCAC TTGCGCTCGT TGATGCCGAT
4261 TCACTAGCAC TAGTAGAAGC TGATTCACTG GCGCTTGTTG ATGCCGATTC GCTGGCACTT
4321 GTCGATGCCG ATTCGCTAGC ACTAGTAGAA GCTGATTCAC TGGCACTTGT CGATGCCGAT
4381 TCACTGGCGC TCGTTGATGC CGATTCGCTG GCACTAGTAG AAGCTGACTC ACTTGCACTT
4441 GTCGATGCCG ATTCACTGGC ACTCGTTGAT GCACTTTCGC TAGCACTCGT TGATGCACTT
4501 TCGCTAGCAC TCGTTGATGC ACTTTCACTT GCGCTCGTTG ATGCAGATTC GCTAGCACTA
4561 GTAGAAGCTG ACTCACTTGC ACTTGTCGAT GCCGATTCAC TGGCACTCGT TGATGCACTT
4621 TCGCTAGCAC TCGTTGATGC ACTTTCACTT GCGCTTGTTG AAGCCGACTC ACTTGCGCTC
4681 GTTGATGCAG ATTCGCTAGC ACTAGTAGAA GCAGATTCAC TTGCGCTCGT TGATGCCGAT
4741 TCACTTGCGC TTGTGGATGC GGACTCACTT GCACTCGTTG ATGCACTTTC ACTTGCACTT
4801 GTGGATGCGG ATTCGCTGGC ACTAGTAGAA GCTGACTCAC TTGCACTCGT TGAAGCACTT
4861 TCACTTGCGC TTGTGGATGC GGACTCACTT GCACTTGTCG ATGCTGATTC GCTAGCACTA
4921 GTAGAAGCTG ATTCACTTGC ACTCGTTGAT GCACTTTCAC TTGCGCTTGT TGAAGCCGAC
4981 TCACTTGCGC TCGTTGATGC CGATTCACTT GCACTCGTTG AGGCACTTTC ACTTGCGCTT
5041 GTTGAAGCCG ACTCACTTGC GCTCGTTGAT GCACTTTCGC TGGCACTTGT CGATGCCGAT
5101 TCGCTGGCAC TAGTAGATGC GGACTCACTT GCGCTCGTTG AAGCCGATTG GCTTGCACTA
5161 GTAGAAGCTG ATTCACTGGC GCTCGTTGAG GCTGATTCAC TGGTACTCGT TGATGCACTT
5221 TCGCTAGCAC TCGTTGAAGC ACTTTCACTT GCGCTTGTGG ATGCGGACTC ACTTGCACTA
5281 GTAGAAGCAG ATTCACTTGC GCTCGTTGAT GCCGATTCAC TTGCACTTGT CGATGCCGAT
5341 TCACTTGCGC TTGTGGATGC GGACTCACTT GCACTCGTTG ATGCACTTTC GCTTGCACTT
5401 GTGGATGCGG ATTCGCTGGC ACTAGTAGAA GCAGATTCAC TTGCGCTCGT TGATGCCGAT
5461 TCACTTGCAC TTGTCGATGC CGATTCACTT GCACTTGTTG AAGCAGATTC ACTTGCGCTC
5521 GTTGAGGCCG ATTCGCTGGC ACTCGTTGAT GCCGATTCGC TAGCACTAGT AGAAGCTGAT
5581 TCACTTGCGC TCGTTGATGC CGATTCACTT GCACTTGTCG ATGCCGATTC ACTGGCGCTT
5641 GTGGATGCGG ACTCACTTGC ACTCGTTGAT GCACTTTCAC TTGCACTTGT GGATGCGGAT
5701 TCGCTGGCAC TTGTCGATGC CGATTCACTG GCGCTTGTTG ATGCGGACTC ACTTGCACTC
5761 GTTGATGCAC TTTCACTTGC ACTTGTGGAT GCGGATTCGC TGGCACTAGT AGAAGCTGAC
5821 TCACTTGCAC TTGTTGAAGC CGATTCACTG GCGCTCGTTG ATGCACTTTC ACTTGTGCTT
5881 GTTGAAGCCG ACTCACTTGC GCTCGTTGAT GCACTTTCAC TTGCGCTCGT TGATGCCGAT
5941 TCACTAGCAC TAGTAGAAGC TGATTCACTG GCGCTTGTTG ATGCAGATTC GCTGGCACTT
6001 GTCGATGCCG ATTCGCTAGC ACTAGTAGAA GCTGATTCAC TTGCGCTCGT TGATGCCGAT
6061 TCGCTAGCAC TTGTCGAAGC TGATTCACTG GCACTCGTTG ATGCACTTTC ACTTGCACTC
6121 GTTGATGCCG ATTCGCTAGC ACTTGTCGAA GCTGATTCAC TTGCGCTCGT TGATGCTGAT
6181 TCACTGGCGC TTGTTGAAGC CGACTCACTT GCGCTCGTTG ATGCACTTTC ACTTGCGCTC
6241 GTTGATGCCG ATTCACTAGC ACTAGTAGAA GCTGATTCAC TGGCGCTTGT CGATGCCGAT
6301 TCGCTAGCAC TTGTCGAAGC TGATTCACTT GCACTCGTTG ATGCTGATTC ACTTGCACTT
6361 GTCGATGCTG ATTCACTTGC GCTCGTTGAT GCTGATTCGC TGGCACTTGT CGATGCCGAT
6421 TCACTTGCGC TTGTTGAAGC TGATTCACTT GCGCTTGTTG ATGCGGATTC GCTTGCACTC
6481 GTTGATGCAC TTTCACTTGC GCTCGTTGAT GCCGATTCGC TGGCGCTCGT TGATGCACTT
6541 TCACTTACGC TCGTTGATGC ACTTTCACTT ACGCTCGTTG ATGCACTTTC ACTTACGCTC
6601 GTTGATGCAC TTTCACTTAC GCTCGTTGAT GCACTTTCAC TTACGCTTTT TGATGCCGAT
6661 TCGCTGGCAC TCCTCGTTGA AGCGGATTCG CTGGCACTCC TCGTTGAAGC GGATTCACTT
6721 ACGCTCGTTG ATGCGCTAGT CGAAGTACTC GTCGAGGTGG ATTCCTGTTC ACTCTTACTC
6781 GTCAATTGA
配列番号31 ラクトバチルス・ロイテリ3630_00804
1 ATGGAGATAT TGGTAACGTT ATTTGATTTG GTGTTTTTTA TTACGTTTAT AGTCGCAATT
61 GTCTATGGTA TTAGGTGGTT TAAAGGAAGA AAAGATAAAG AAAATGAATC TCTTAAGAAA
121 CGCCGTTTGT AA
配列番号32 ラクトバチルス・ロイテリ3630_00827
1 ATGATTAACT TAAACTTAGC AGGCTTAGAT TTTGTAATGA CGGCACTTTT TATTGTGTTG
61 TTTACAGAAC AGTTGAAAAA TGCCCGAACT CAGCGTGATG CTCTGATTGG TTTAGCATTT
121 GCAATTATTT GTTTACTATT TTGCAACAAG AATGTTTTTC TATTAGTGAC ATTAGTAACA
181 CTTGTCGCAC TGTTTTCATT AAATTACTTA ATCACGAGGA GAAAAAATGA CATTAACTGA
配列番号33 ラクトバチルス・ロイテリ3630_00947
1 ATGTCAGAGA TGAAAAATCG CGTAATTAAT TTTCGGAATG ATAACTTAGC CAAACTTATA
61 GTCAATTATT ATGGAAATAG TCAATTAAGT GTGCATATTA CTAATAATAT GTTTTTTGAA
121 TGA
配列番号34 ラクトバチルス・ロイテリ3630_01261
1 ATGAAACGCA AAATTGCATT AGCTCAACTT GATATTCAAT TAGGAAATCC TGCCGAAAAT
61 TATCAAAAAG CTAAACAAGC GATTGAAGAA GCTGCTAGTC ACCATGCAGA TATCGTTGTC
121 TTGCCGGAGA TGTGGAATGC TGGCTATGCC TTAGATCAAT TAGCAGAATT GGCAGATGAA
181 AACGGTCAAA AGACACAAAA ATTTCTTAGT GAGTTAGCGT TAGAAAATCA AATTAACATT
241 GTCGGTGGTT CAGTAGCGGT GAGATGTGGA CAATCTTTTT TCAATACAAC CTATGTTTAT
301 GATCAAAAGG GAAATCTAAT TAGCAGTTAC GAGAAGGTGC ATTTATTTGG ACTAATGAAT
361 GAAGACCGAT ATCTAAAAGC CGGGCAAAAA GAAAATCACT TTGAATTAGC TGGGGTTCCG
421 AGTGCAAGTT TTATTTGTTA TGATTTGCGA TTCCCTGAAT GGATTAGAAC AGTCACTCGT
481 TATGGAACTG ATATCTTATA TTTTTCGGCA GAATGGCCAA GCAAACGGAT TAAACAATGG
541 AAAATAATGC TTCAGTCACG GGCAATTGAA AATCAAGCCT TTGTAGTCGC GGTCAATCGT
601 GTTGGGACGG ATTTAGAGAA TAGCTTTAAT GGTCATTCGT TAGTAATAGA TCCGCTTGGG
661 CAGATTATCC ATGATGCAGG AGAAGTTGAA CAAGTAAGTT ATGCAGAAAT TGACTTAGCG
721 CAGTTAGCAC AGGTTCGGGG GCCGATTCCG GTGTTTAAGG ATCGCCGACC AAGTCTTTAT
781 CATTAA
配列番号35 ラクトバチルス・ロイテリ3630_01695
1 ATGCAAAATA AAGATGCTTG TACATCAATT ATGGTCGGTA AAAAGGCTTC TCTCGACGGT
61 GCTAATTATA TTGCTCGTAA TGAAGATCGC GTAAAAGCAA TTGAACCCAA GCGATTTTTA
121 GTAAAACCGG CAGTAAAAGG ACGCCACGAA ACCTACGTAT CACCTTACAA TAAAGTAACT
181 GTAGCTTTGC CGGAAGAGAG AATGCGTTAT ACTTCTACGC CTACCCTTGA TCAAACAGCC
241 GGACCTAATG AAGAAGATGG AATTAATGAA GCAAATGTGG CAGCTTCCTT TACTGAGAGT
301 GTTTATGCAA ATGATCGGGT GTTAGCATAT GATCCATACG TAAAAAATGG CCTGGCAGAA
361 GACTCACTTT GTACTTTAGT ATTACCGTAT ATTCATTCTG CCCGTGAAGG AGTTGAATAT
421 ACTGGAAAAT TAATTGCTGA ATTGGGCTCT GCTGAGGGAA ATGGAATGCA ATTTGCAGAT
481 GCAGATGATA TTTGGTATAT GTAA
配列番号36 ラクトバチルス・ロイテリ3630_01889
1 ATGAATTATT TTATCGGTGT TGATGTTGGA ACTACTTCTA CAAAGGCAGT TCTATATGAC
61 CAAAATGCAA CTGTGTTAGA TCAATTTAGC CAAGGTTATT CCCTTTACCG CGATGCTAGT
121 GGAATGGCTG AACAAAACCC AACTGCAATT GTCGAAGCAG TCGAAAAAGT TATTCATGAT
181 GCAGCACAAA AAGCAGATTT AACAAATGGA AAATTGTTAG CGGTATCATT TTCTAGTGCT
241 AACCAAAGTG TGATTATGCT CGACAAGAAT TTCAATCCCC TTTCACGGGT CATCACTTGG
301 GCTGATACCC GTGCACGTGA TGTCGCCAAC GAATTAAAGA ATAGTCCTGC TGGTCAGCAA
361 ATCTATGCTA AAACAGGTAC ACCTATTCAT CCAATGTCCC CATTGACCAA GATTATGTGG
421 CTCAATAAGA CACAAGCAGA TAAGGTTGCT CAAACTGCAT ATTTTGGCGA TATCAAATCC
481 TACCTCTTCC ACCAGTTTTT CAATACATTT AAGGTTGATG TTTCCATCGC TTCATGTACC
541 GGAATGATGA ATGTCAATAC GTGTGACTGG GACGATCAAG CATTGGAACT CGCTAACGTC
601 GACTGTTCCC AATTACCAGA AATCGTGAAC GGAACAACCC AAGCGATTGG CCTAACAGCA
661 GCGGCGCAAG CAAAAATGGG TATCCCCGCT GACACGCCAT TTGTCTATGG TGCCTTTGAC
721 GGTGCTTTAT CTAATTTAGG TGTGGGGGCA ATTAAGCAAA ATACTGTTGC CATTACGATT
781 GGAACTTCGG CTGGTGTTCG GGTAGTAACT GACCATCCAG TGATCGATCC TCAGCAACGA
841 CTCTTCTGTT ACGCCGTGGA TAAAGGTTTA TGGGTCATCG GCGGTCCGCT TAATAATGGT
901 GGCGATGTCT ATCAGTGGGC CGTTGAACAC TTAGTTGACG CTAGTGCAGT TAAAAATGAA
961 AATATTGATC CCTACACTCT TGCTAACCGA GTTATTGAAG GTGTTCCCGC CGGAGCTCAC
1021 GGTTTGCTCT TCCACCCATT CCTTGGCGGT GAACGGGCAC CATTATGGGA CGCTAATGCG
1081 CGCGGTAGTT TCTTTGGACT TTCCCACATT CATACTCGTG CCGATATGCT GCGCTCAGTA
1141 ATGGAAGGAA TTTGTATGAA TATTGCAACT GTTTTCCAAG CGGTTCGTGA TCTTGTTGGT
1201 AATCCTGCAA GCGTAACTGC AACTGGCGGT TTTGCGCGAG CTGAAGTTTG GCGGCAAATG
1261 TTAGCAGATG TCTTGAACTG TCCGGTCAAT ATCCCGAACT CATTTGAATC TGGTTGTCTC
1321 GGTGCAATCA CCATGGCAAT GAAGAGTTTA GGAATGATTG AAAACTATGA AATCATTAAA
1381 ACATTAGTTG GTGATATCAG TTCTTATCAG CCAAATCAAG ATGCGGTTAA TGTTTATCAA
1441 AATTACTTAC CACTTTTTAA GCAGGTCGAA GGATTATTAA CACCAGCCTA TTCGACCATC
1501 GCTAAATTAC AACAACAATC TACTACTCAT TAG
配列番号37 ラクトバチルス・ロイテリ3630_01932
1 ATGACAACAT CAATGATCCA CAGTAGAAGT ATGTTGGCGA AAGTGATTGC AGAATCACCT
61 TCACCTTTTA TTATACCAAT TTTTTGTCCT AATGTAATAA AGATTATCTT TTTATCTATA
121 AATTATTTTA TGAAAAGAGT GGAAAAGGCA AGAAGAGCAA TCAAAAAGCC AATTTTAACA
181 ATTTTATTAA GTTGA
配列番号38 ラクトバチルス・ロイテリ3630_02243
1 ATGAGCAAAC TATTACTTGA TGAAAGACCG TTACAAGTTC AGGCATCGTT AGCTGGAGCG
61 TTGAAAAGCT TAGACGAAGC TGTTATTCTC CAGCAGCTTC ACTATTGGCT TCAACGTTCT
121 AATACAGTAA GAGACAATCA CAAATGGGTC TATAACAGCA TGGCTGATTG GAATAAACAG
181 TTCCCTTGGC TTTCTAGAAA GGCTCTATCG AACCACTTTA AGAAATTAGA AAAACGAGGA
241 CTAATTATTA CAGGCAACTA TAATAAATTA TCTTTTGACA AAACAAAGTG GTATCGAATT
301 GACTATGACG CATTTTCCCA TTTGGAACAA CGATTGGGTA GAAACTACCC AACGAATGGG
361 AAGAATCTAC CCAATGGAGA CGGTAAAAAC TGCCCAATCG GAGAGGAAGA ATCTACCCAA
421 CCAATACCAA TAGACTACCA AGAGACTACA CAAAAGACTA CTACAAGAGA TAAAGGGCAG
481 GCACAGCCAG CCCAACCTTC CATTGCTGCA CAGCGGCGAG AAGTTGTTGA ATATCTCAAT
541 CAAAAAAACT GGCAAGCACT TCAAGCCTGA
配列番号39 ラクトバチルス・ロイテリ3630_02365
1 TTGAATAATT TTCAAAAGGC AATTTTCTTG TTGCAGAATA TCGACAAGCT TAAACAGCTT
61 AATGGTAAAG CGATGACTCT TACTGAGTTC TCTAAAATAA CTGATGTTTC ACGGCCAACG
121 TTGTATAAAT ACATTCAGCA TCCAGAAACA ATGAGTAGTT CGTTTGTAAA TAAAGCGGCC
181 ATGCTCTACG ACAAGGTTGT TAAATTTCAA GATATTCTTG ATACAGTTCA GCGTGAAGAT
241 AAACAATTTA AGACTACCAG GCAGGAATTG ATTAAGCTTT TAGAGTCTAA TGTAGCTAAT
301 ATTGAAGTTA CAGATTATAC AAAAGCAATC GCGACAGTAA TTATTAGTGA CTTAAAAGAA
361 GAAAATTCAA GTCTGCTAAA AGCGTTAAGT AAGCAATTAC CATTTAAACC AAATTTAAAT
421 GATAATTTGT CAAAATAG
配列番号40 ラクトバチルス・ロイテリ3630_02435
1 GTGAAGATGA ATAGTATGAC AAACAACCAA AAAGAAAGTT GGAACGTTGG CAACTATAAA
61 ATCAATGTAT TACCAGATGA TGAGTTCCAG CAATTGTTAA AGAACCAACG CCAACTTCAA
121 CAGATCATTG AAAGTATGCC ACTACCAACC GACCCCAATG TTGATCTAGT TAAAAAGATT
181 CATTCCCAAC TCCCTATTAC AAACTGGGCT TGGGAATTAA CTAAACAACG AGAACATGAG
241 GAAAAGTTAA AGAAACAAAA GCAGCGAATT GCACAGCAAT CGCTTAACTA TCCAACAAAC
301 CTCAAGAAAC CGGATAATGG CCTTTCCCTA TAA
配列番号41 ラクトバチルス・ロイテリ3630_02436
1 ATGAATTCTA ATTTGAAAAA GAATTTGATT ATCGCAAATG GATTTCTACT ACTAATAATA
61 ATATTTTATG TTTTATTACA TATGGGTCCA TTAAATATGA AAGTCTTATT AGTAGGATTG
121 GTATTAATGA ATCTGACAGT AATATTTAAA TAA
配列番号42 ラクトバチルス・ロイテリ3630_02437
1 ATGGATAAAT TAACATTGAA AAAACTAATT ATTATTACAT TAGGCATGCT AATGGTATTT
61 CTTTTAGGTA TGCACCTTCA TCAAAAGACA CACTTTAACA AAAACGTGAA GATTAATAAT
121 ATTCCAGTCG GAGGTCTTAC TGTTCAACAG GCATATAATA AAGTAAGTAA TACTAAAAGA
181 AAATCAAAAA TCTACATTAA CAAAAAGTTA GTTTATTCAG GTAAAAGTAC TGACTCAGGT
241 TTTAAGTTAT CTGATAAAGA AAGATTTAGT AAGGCGTTAC ATTACCAATA CACTTTTTTT
301 CCCTCACGAA AACATGAAAA TTTGCTAGTT GAGCCAGCTG ATTTAGATAA GTCAGCGTTA
361 AATAATATTG ATTCGGCAAT AGTAGCTAGG ATTCATCAGC TCAATATAGG CAGAAAGGCC
421 CCACGTGATG CATACGCCGT TTACCAGAAT AATAAAGTTT CAGTTATTCC AGCAATTGAT
481 GGGACACGAT ATAGTGAACA AGGACTTTGT AATATTGCTA ATAAGGAATT TGTTAATGGG
541 ACAATTCATT TAACTCCTAA GGTTATTACT CCTTTATCGG CAAACAGTAA AGTAGTTCAA
601 GATGAAAAGA AACACCTGAG TAAACTACAA AATCGATCGG TTGTTTATCA GGTTCAGAAA
661 ACAAAATATA ATTTTAAAGC GTCTAATGTC ATTTCTAAAG CAACTTATCA GCATGGGAAA
721 TACCATTTTG AAACTGACAA CGTTAAATCC AAGATTGCCA ATATAAATAA TAAGCAAGCA
781 ACATTAGGAA AGAGCTTTAA ATTTAGAACT GATTCTGGAA AAGTTATTTC TACATCTAAT
841 CAGGGAACAT ATGGTTGGAA AATAAGTAGC AAGCAGGCAG GACAAACACT CTCTAAAGCG
901 TTAGCTAATA ATGTTAAGAG CGTTAATGCC GAAAATGATA TTTACGGTAA AGGCTATAGT
961 CATCTTGGTA CTGGATATTC GGCTGTGAAT AATCATGGGC TTGGTAATAC TTATGTGGCT
1021 GTATCATTAG CTAAACAGCA TGCTTGGTTT TATAAAAATG GAAAATGTGT ACTGAGTACA
1081 GATATTGTTA GTGGATCAGA TGACGCTAAT AATAGGACTC CTAAAGGTGT TTGGTATATC
1141 ATGTATCAAC AAACGCCATC AGTTTTACGT GGGACTAATG ATGATGGTTC CAAGTATAGT
1201 AGTCCTGTTC AGTATTGGTC TCCGTTTACT TTATCAGGGT GTGGCTTTCA TGATGCTAGT
1261 TGGAGGCATA ATTGGTCTAA AACAGCTTAT AAACAGACTC ATGGTGGCTC ACATGGCTGT
1321 ATTAACATGC ATCCGGAAAA TGCAGGAGAC GGTTTCCATG CCCTTACTAA AGGAGAACCG
1381 GTAATAATTT ATTAG
配列番号43 ラクトバチルス・ロイテリ3630_02438
1 ATGCAATTAA ACCATAAATT AGGAGTTTTC TTGGCAGCGC CATTTGCTCT ACTGGTTTTA
61 TCAGCTACAA ACGTGCATGC CGATAACATT CAAAGTAATA GTAACCAGAC AATCAGTAAT
121 ATGAGTTTGC AAACTAATGA CACAAAGACT CAACAAAATG TTGTAATGTC AAACGATGCA
181 AAAGCTCAAA TTACTGTAAA TCCTAGTTCT AATGCTAATT CTAGTTCTGT AGCAAAGATA
241 AATGAAAAGA ATAATGTAAA ATCGGATACT GACAATACTA ATGTCGAATC AAATGCTGAT
301 AATATTGGGA ACATTGCTTC TAGCGATTCC ACGGCAGTGG CTAATTCTGC TAGTTCCGAT
361 AATATTCAGT CATTTAACGT AAATACGCAG GAACAGCCTG CAATAAATGT ATCTGAACTA
421 ACAACCGAAG AGTATGTTAC GAATTACACT CAACAACAGA TCAATAATGC GACGACTATT
481 CATGATTACT TTATAAATCA AGGATGGACA CCAAATGCTA TTGCTGGAAT GCTTGGTAAC
541 TTTGTTTCAG AGTCAGGTTT AATCCCAGAC TTACATCAAT ATGGTGGTGG GCCTGGTTAT
601 GGGTTAGCTC AATGGCCATT TAATAGTGTA GTAAATTGGT GTCGTAATAA TGGATATGAT
661 TATCGTACTT TGCAAGGACA ATGTGCATAT ATTGAATATC AAATGACTCA TGGACAGCAG
721 TATTATCCAT CAGCTTACTC TAGAATGACC GCTAATGAAT ATATGCATAG TTATGCTTCA
781 GCATATACTT TAGGTATGAT TTGGCTTAAT AACTTTGAGC GACCTGCAAA TAGGAATCAG
841 CCAGCTCGTG GTCAACAGGC TCAATACTGG TATCAGTATT TCCAAAGTCA TGGTTCTACA
901 TCAGCACCGG TACAACAAAA TCCTAGTACA CCAGCAACAA CTCCTAGCTC AAGTCGAATG
961 AGTCAACACG GGACATTCAA AGTTGCTTAT GGATTAAATG TACGCCAAGC ACCAAGTACA
1021 TCGGCAGCTA TTGTAACGTA TTACAATGGT GGTCAAAGCT TTACATATGA TTCAAAGATT
1081 GAAGCTAACG GGTATCTTTG GGTATCATAC ATGAGTTATA GTGGCGTACG TCGTTATGTT
1141 GCAATTAAGA ATTTGAATAA TGGAACGACT TACGGTTATG ATTCGAATAA CTTCTCATAC
1201 AGTGCTCCTG CATCTTCAAC ACCATCTACT AATGTGCCAA GTACGCCAGC ACCAAGTACA
1261 TCTACTTCAT CAACTGAGAA GCAATATGGA ACATTCAAAG TTGCTTATGG ATTAAATGTA
1321 CGCCAAGCAC CAAGTACATC GGCAGCTATT GTAACGTATT ACAATGGTGG TCAAAGCTTT
1381 ACATATGATT CAAAGATTGA AGCTAATGGG TATCTTTGGG TATCATACAT GAGTTATAGT
1441 GGCGTACGTC GTTATGTTGC GATTAAGAAT TTGAGTAATG GAACAACTTA CGGTTACGAT
1501 TCAAATAACT TTTCATTTAA TGGGACTCCA GTAACATCAA ATAATAATCC TTCTAGTACT
1561 CCGGCAGTTC CGCAAGGTAA TAAGGGCCAA CAAGTTGTTG CTCTTGCACG TCAACAAATA
1621 GGTAAACCTT ATGTTTGGGG AGCAACCGGT CCTAATTCGT TTGATTGTTC AGGACTCGTG
1681 CAGTATGTTT ATCGTCAAGT TGGTGTTAAC TTACCACGGA CTACAACTCA ACAAGAATAT
1741 TGTGGACATG CTGTAAGCTT TAATAATCTT CAACCTGGAG ATCTAATGTT CTGGGGAAAG
1801 TATGGTAGTG CATATCACGT TGGAATCTAT ACCGGAAACG GTAATGTTTT ATTTGCACCG
1861 CAACCTGGTC AAACAGTTAA GGAACAACCA ATGCGCTATT ACATGCCTGC CTTTGCAAGA
1921 AGAGTATTGT AA
L.ロイテリ菌株特定。
Research Center、Hannoverで老齢のトリからHannover大学のPoultry Clinicから受け取った盲腸内容物から7種のラクトバチルス・ロイテリ(L.ロイテリ)菌株を単離した。7種すべての菌株を、16S rRNAシークエンシングによってL.ロイテリであると確認する。
L.ロイテリ菌株の選択及び抗感染活性。
プロバイオティクスとして更に使用するための最良の菌株を選択するために、L.ロイテリ分離株を、増殖速度、過酸化水素を産生する能力、自己凝集、酵素プロフィール、ウシ胆汁及び膵臓酵素の存在下における生存、並びに熱ショック及びpH変化に対する感受性等のさまざまな望ましいプロバイオティック抗感染特性に関して試験した。L.ロイテリ菌株はまた、溶血アッセイを使用して安全性に関しても試験する。
16日齢の胚におけるL.ロイテリ3632の定着
本研究の目的は、L.ロイテリ3632が16日齢の胚の腸に定着するかどうかを試験することであった。この目的を達成するために、16日齢の胚をCharles River社から入手し、108CFU/胚のL.ロイテリ3632を気室、卵黄嚢及び尿膜経路により接種した。胚を18日目に屠殺し、腸を回収し、MRS寒天プレートに播いた。対照として未接種群が含まれた。大半の胚の腸からL.ロイテリが回収され、これは、L.ロイテリ3632が16日齢の胚の腸に定着することを示唆する。液体培養物における2日間の濃縮後でも、対照(未接種)胚のいずれからもL.ロイテリ3632は回収されなかった。
ブレインハートインフュージョン(BHI)培養液におけるL.ロイテリ及びC.パーフリンジェンスの共培養。
L.ロイテリ及びC.パーフリンジェンスをBHI培養液中で培養した。BHI培養液中における共培養の24時間後にCFU数を求めた。L.ロイテリをMRS寒天プレート上で数え、C.パーフリンジェンスをOPSPプレート上で数えた。このデータは、3回の反復実験のうちの代表的な1回の実験からのものである。共培養-L.ロイテリ、L.ロイテリ特異的培地を使用した共培養サンプルから回収されたL.ロイテリ。共培養-C.パーフリンジェンス、C.パーフリンジェンス特異的培地を使用した共培養サンプルから回収されたC.パーフリンジェンス。図9を参照。
L.ロイテリのインビボ効果
0日目にトリにCocciVacのワクチン接種をし、0日目から42日目に107CFU/Kg飼料の飼料中のL.ロイテリを与えた。別個の群のトリにバシトラシンメチレンジサリチラート(BMD_55)を加えた飼料を与えた。
ラクトバチルス・ロイテリの増殖に対するプレバイオティクスの効果。
L.ロイテリ菌株3630及び3632を、個々に及び組み合わせで、フルクトオリゴ糖(FOS)、アラビノキシランオリゴ糖(AXOS)、マンナンオリゴ糖(MOS)、又はガラクトオリゴ糖(GOS)を含む、いくつかの異なるプレバイオティクスの存在下において増殖させた。
L.ロイテリのインビボ効果
特定された菌株は、菌株が宿主の胃腸管に定着することができる場合にのみ、直接給与生菌として効果的に機能することができる。L.ロイテリ菌株のニワトリに定着する能力を、さまざまな投与経路に従って評価する。
壊死性腸炎モデル。
L.ロイテリを1日当たり108CFU/トリで卵内及び飲用水に投与した。14日目にトリにE.マキシマ(maxima)を経口強制投与した。18、19、及び20日目にトリに108CFU/トリでC.パーフリンジェンスを経口強制投与した。
網羅的メタボロミクス分析。
L.ロイテリ菌株3632及び3630の網羅的メタボロミクス分析を行った。菌株を個々に及び組み合わせて増殖させ、細胞ペレット及び培養物の上清中のさまざまな分子を分析した。グルコースを含まないが、0.5% GOSを含むAOF-MRS培地対照中において菌株を増殖させた。上清中の分子は、細胞によって分泌される分子である。
1. 第1の単離ラクトバチルス・ロイテリ菌株及び第2の単離ラクトバチルス・ロイテリ菌株のうちの少なくとも1つを含む組成物であって、
該組成物は、有効量が動物に投与されると、該組成物を投与されていない動物と比較して、動物の健康を高める、組成物。
配列番号26と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列、
配列番号1と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列、
配列番号3と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列、及び
配列番号8と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有するアミノ酸配列をコードする核酸のうちの少なくとも1つを含み、
該第2の単離ラクトバチルス・ロイテリ菌株は、
配列番号25と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列、
配列番号27と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列、
配列番号28と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列、及び
配列番号29と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列のうちの少なくとも1つを含む、実施形態1に記載の組成物。
該第2の単離ラクトバチルス・ロイテリ菌株は、配列番号25と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列を含む、実施形態1~5のいずれか1つに記載の組成物。
動物に有効量の実施形態1~41のいずれか1つに記載の組成物を投与する工程を含む、方法。
Claims (45)
- 第1の単離ラクトバチルス・ロイテリ菌株及び第2の単離ラクトバチルス・ロイテリ菌株のうちの少なくとも1つを含む組成物であって、
有効量が動物に投与されると、前記組成物を投与されていない動物と比較して、動物の健康を高める、組成物。 - 前記第1のラクトバチルス・ロイテリ菌株は、
配列番号26と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列、
配列番号1と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列、
配列番号3と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列、及び
配列番号8と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有するアミノ酸配列をコードする核酸のうちの少なくとも1つを含み、
前記第2の単離ラクトバチルス・ロイテリ菌株は、
配列番号25と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列、
配列番号27と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列、
配列番号28と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列、及び
配列番号29と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列のうちの少なくとも1つを含む、請求項1に記載の組成物。 - 前記第1の単離ラクトバチルス・ロイテリ菌株は、配列番号26と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列を含む、請求項1又は2に記載の組成物。
- 前記第2の単離ラクトバチルス・ロイテリ菌株は、配列番号25と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列を含む、請求項1~3のいずれか一項に記載の組成物。
- 配列番号25と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列;及び配列番号1と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列を含む第1の単離ラクトバチルス・ロイテリ菌株を含む、請求項1~4のいずれか一項に記載の組成物。
- 前記第1の単離ラクトバチルス・ロイテリ菌株は、配列番号26と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列を含み、
前記第2の単離ラクトバチルス・ロイテリ菌株は、配列番号25と少なくとも95%、少なくとも96%、少なくとも97%、少なくとも98%、又は少なくとも99%の配列同一性を有する核酸配列を含む、請求項1~5のいずれか一項に記載の組成物。 - 前記第1のラクトバチルス菌株及び第2のラクトバチルス菌株のうちの少なくとも1つは、環状ジペプチド、短鎖脂肪酸、ベタイン、ジメチルグリシン、必須アミノ酸、ヌクレオチド、ミオイノシトール、及びインドリン-2-オンのうちの少なくとも1つを分泌する、請求項1~6のいずれか一項に記載の組成物。
- 0.75~1.5:1の第1の単離ラクトバチルス・ロイテリ菌株の第2の単離ラクトバチルス・ロイテリ菌株に対する比を含む、請求項1~7のいずれか一項に記載の組成物。
- およそ同じ量の前記第1の単離ラクトバチルス・ロイテリ菌株及び前記第2の単離ラクトバチルス・ロイテリ菌株を含む、請求項1~8のいずれか一項に記載の組成物。
- 動物飼料、飼料添加物、飼料成分、水添加物、水混合添加物、摂取可能な溶液、摂取可能な噴霧添加物、摂取可能な固形物、摂取可能なゲル、注射、又はそれらの組み合わせとして配合される、請求項1~9のいずれか一項に記載の組成物。
- 動物飼料を含む、請求項1~10のいずれか一項に記載の組成物。
- 前記第1の単離ラクトバチルス・ロイテリ菌株を約102~108CFU/kg組成物、約104~107CFU/kg組成物、又は約103~105CFU/kg組成物の量で含む、請求項11に記載の組成物。
- 第2の単離ラクトバチルス・ロイテリ菌株を約102~108CFU/kg組成物、約104~107CFU/kg組成物、又は約103~105CFU/kg組成物の量で含む、請求項10~12のいずれか一項に記載の組成物。
- 前記第1の単離ラクトバチルス・ロイテリ菌株を約107CFU/kg組成物の量で含む、請求項10~13のいずれか一項に記載の組成物。
- 第2の単離ラクトバチルス・ロイテリ菌株を約107CFU/kg組成物の量で含む、請求項10~14のいずれか一項に記載の組成物。
- 水を含む、請求項1~15のいずれか一項に記載の組成物。
- 前記動物は、トリ、家禽、ヒト、又は非ヒト哺乳動物である、請求項1~16のいずれか一項に記載の組成物。
- 前記動物は、家禽であり、家禽の健康を高めることは、飼料転換率の低下、体重の増加、除脂肪体重の増加、胃腸管における病原体関連病変形成の減少、病原体の定着の低減、及び死亡率の低下のうちの少なくとも1つを含む、請求項1~17のいずれか一項に記載の組成物。
- 家禽の健康を高めることは、飼料転換率の少なくとも1%、少なくとも5%、少なくとも25%、又は少なくとも50%の低下を含む、請求項18に記載の組成物。
- 家禽の健康を高めることは、家禽体重の少なくとも1%、少なくとも5%、少なくとも25%、又は少なくとも50%の増加を含む、請求項17~19のいずれか一項に記載の組成物。
- 家禽の健康を高めることは、胃腸管における病原体関連病変形成の少なくとも1%、少なくとも5%、少なくとも25%、又は少なくとも50%の減少を含む、請求項17~20のいずれか一項に記載の組成物。
- 家禽の健康を高めることは、死亡率の少なくとも1%、少なくとも5%、少なくとも25%、又は少なくとも50%の低下を含む、請求項17~21のいずれか一項に記載の組成物。
- 前記病原体は、サルモネラ、クロストリジウム、カンピロバクター、ブドウ球菌、ストレプトコッカス、及び大腸菌のうちの少なくとも1つを含む、請求項18~22のいずれか一項に記載の組成物。
- 前記病原体は、ネズミチフス菌、サルモネラ・インファンティス、サルモネラ・ハダル、腸炎菌、サルモネラ・ニューポート、サルモネラ・ケンタッキー、クロストリジウム・パーフリンジェンス、黄色ブドウ球菌、ストレプトコッカス・ウベリス、ブタ連鎖球菌、大腸菌、カンピロバクター・ジェジュニ、及びフソバクテリウム・ネクロホラムのうちの少なくとも1つを含む、請求項18~23のいずれか一項に記載の組成物。
- 投与されることは、卵内投与を含む、請求項17~24のいずれか一項に記載の組成物。
- 投与されることは、噴霧投与を含む、請求項17~25のいずれか一項に記載の組成物。
- 前記家禽は、ニワトリである、請求項17~26のいずれか一項に記載の組成物。
- 前記家禽は、ブロイラー鶏である、請求項17~27のいずれか一項に記載の組成物。
- 前記家禽は、産卵鶏である、請求項17~27のいずれか一項に記載の組成物。
- 前記組成物を投与された前記動物は、前記組成物を投与されていない動物と比較して、少なくとも1つの改善された消化管の特徴を更に示し、改善された消化管の特徴は、環状ジペプチドの増加、短鎖脂肪酸の増加、ベタインの増加、ジメチルグリシンの増加、必須アミノ酸の増加、ヌクレオチドの増加、及びミオイノシトールの増加を含む、請求項1~29のいずれか一項に記載の組成物。
- 前記組成物を投与された前記動物は、胃腸管のマイクロバイオーム内容物に変化を示す、請求項1~30のいずれか一項に記載の組成物。
- 前記変化は、バクテロイデス科細菌の量の増加を含む、請求項31に記載の組成物。
- 投与されることは、ワクチンの投与を含む、請求項1~32のいずれか一項に記載の組成物。
- 前記動物は、家禽であり、前記家禽は、前記組成物の前記投与に先立ってワクチンを投与される、請求項1~33のいずれか一項に記載の組成物。
- 前記動物は、家禽であり、前記家禽は、前記投与と同時にワクチンを投与される、請求項1~34のいずれか一項に記載の組成物。
- 前記動物は、家禽であり、前記家禽は、ワクチンを投与され、前記ワクチンは、コクシジウム症の予防を助けるワクチンを含む、請求項33~35のいずれか一項に記載の組成物。
- 投与されることは、ガラクトオリゴ糖(GOS)の投与を含む、請求項1~36のいずれか一項に記載の組成物。
- 治療に使用するための、請求項1~37のいずれか一項に記載の組成物。
- 動物の健康を増進させることに使用するための、請求項1~38のいずれか一項に記載の組成物。
- 病原性細菌の動物への定着を低減することに使用するための、請求項1~39のいずれか一項に記載の組成物。
- 病原性細菌の動物への定着を低減するための医薬の製造に使用するための、請求項1~40のいずれか一項に記載の組成物。
- 動物の健康を高めるための方法であって、
動物に有効量の請求項1~41のいずれか一項に記載の組成物を投与する工程を含む、方法。 - 前記動物は、家禽である、請求項42に記載の方法。
- 動物の健康を高めることは、胃腸管における病原体関連病変形成の減少、病原体の定着の低減、及び死亡率の低下を含む、請求項42又は43に記載の方法。
- 請求項1~29のいずれか一項に記載の組成物を、それを必要とする家禽に投与することによって、家禽の壊死性腸炎を処置する、その影響を改善する、又はそれを予防する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962801307P | 2019-02-05 | 2019-02-05 | |
US62/801,307 | 2019-02-05 | ||
PCT/US2020/016668 WO2020163398A1 (en) | 2019-02-05 | 2020-02-04 | Probiotic compositions comprising lactobacillus reuteri strains and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022520553A true JP2022520553A (ja) | 2022-03-31 |
Family
ID=69771081
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021546017A Pending JP2022519699A (ja) | 2019-02-05 | 2020-02-04 | 遺伝子改変ラクトバチルス(Lactobacillus)及びその使用 |
JP2021546018A Pending JP2022520553A (ja) | 2019-02-05 | 2020-02-04 | ラクトバチルス・ロイテリ(Lactobacillus Reuteri)菌株を含むプロバイオティック組成物及び使用方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021546017A Pending JP2022519699A (ja) | 2019-02-05 | 2020-02-04 | 遺伝子改変ラクトバチルス(Lactobacillus)及びその使用 |
Country Status (10)
Country | Link |
---|---|
US (3) | US20220127628A1 (ja) |
EP (2) | EP3921425A1 (ja) |
JP (2) | JP2022519699A (ja) |
CN (2) | CN113677799A (ja) |
AU (4) | AU2020218748B2 (ja) |
BR (2) | BR112021015289A2 (ja) |
CA (2) | CA3127806A1 (ja) |
MX (2) | MX2021009398A (ja) |
WO (2) | WO2020163284A1 (ja) |
ZA (2) | ZA202105312B (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11130800B2 (en) | 2016-05-20 | 2021-09-28 | Novobind Livestock Therapeutics Inc. | Antibodies against microorganisms and uses thereof |
CN112703201A (zh) * | 2018-07-05 | 2021-04-23 | 诺沃班德畜牧业治疗公司 | 针对家禽致病原的抗体和其用途 |
WO2022103837A1 (en) * | 2020-11-10 | 2022-05-19 | Elanco Us Inc. | Immunogenic probiotic compositions and methods of use including in vaccination |
WO2023044158A1 (en) * | 2021-09-20 | 2023-03-23 | Biomedit, Llc | Multivalent anti-campylobacter antibodies and vaccine |
WO2023049300A1 (en) * | 2021-09-22 | 2023-03-30 | Biomedit, Llc | Methods of inhibiting diseases caused by respiratory viruses |
WO2023076353A1 (en) * | 2021-10-26 | 2023-05-04 | Biomedit, Llc | Probiotic lactobacillus strain compositions and applications therefor including for leaky gut and inflammation |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT700998E (pt) | 1994-09-12 | 2004-03-31 | Aventis Pharma Gmbh | Mersacidina recombinante e metodo para a sua producao |
US6100388A (en) * | 1998-03-16 | 2000-08-08 | Biogaia Biologies Ab | Lactobacilli harboring aggregation gene as a vaccine delivery vehicle |
WO2010077682A2 (en) * | 2008-12-08 | 2010-07-08 | James Allen Lemke | Treatment of hiv and aids using probiotic lactobacillus reuteri |
GB2482535A (en) | 2010-08-05 | 2012-02-08 | Hera Pharmaceuticals Inc | Expression of antibody or a fragment thereof in lactobacillus |
CN102010849B (zh) * | 2010-11-18 | 2013-09-04 | 广东天浩生物工程股份有限公司 | 猪白细胞介素10重组乳酸菌及其应用 |
DE102011015803A1 (de) * | 2011-04-01 | 2012-10-04 | Abitep Gmbh | Mittel zur Behandlung von mikrobiellen Erkrankungen bei Kulturpflanzen |
MX2014013586A (es) * | 2012-05-09 | 2015-06-05 | Contrafect Corp | Lisina de bacteriófago y combinaciones de antibióticos contra bacterias gram positivas. |
PL3456334T3 (pl) * | 2012-06-04 | 2021-05-04 | Biogaia Ab | Bakterie kwasu mlekowego do stosowania dla zapobiegania ubytkowi masy kostnej u ssaków |
BR112017023707B1 (pt) * | 2015-05-05 | 2022-03-29 | The Regents Of The University Of California | Composição, uso de uma composição, vetor recombinante, microrganismo transgênico, e polipeptídeo recombinante |
CN105219683B (zh) * | 2015-11-04 | 2018-03-13 | 广东省农业科学院动物科学研究所 | 一株具有益生特征的罗伊氏乳杆菌菌株及其应用 |
WO2017123675A1 (en) * | 2016-01-11 | 2017-07-20 | Synlogic, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
US11684643B2 (en) * | 2017-02-17 | 2023-06-27 | The University Of British Columbia | Probiotic compositions and uses thereof |
CN107961373A (zh) * | 2017-11-14 | 2018-04-27 | 东北农业大学 | 一种用于预防猪流行性腹泻的基因工程亚单位口服疫苗株及其构建方法和用途 |
-
2020
- 2020-02-04 CA CA3127806A patent/CA3127806A1/en active Pending
- 2020-02-04 JP JP2021546017A patent/JP2022519699A/ja active Pending
- 2020-02-04 WO PCT/US2020/016522 patent/WO2020163284A1/en unknown
- 2020-02-04 CA CA3127898A patent/CA3127898A1/en active Pending
- 2020-02-04 US US17/428,506 patent/US20220127628A1/en active Pending
- 2020-02-04 BR BR112021015289-0A patent/BR112021015289A2/pt unknown
- 2020-02-04 WO PCT/US2020/016668 patent/WO2020163398A1/en active Application Filing
- 2020-02-04 EP EP20709869.0A patent/EP3921425A1/en active Pending
- 2020-02-04 AU AU2020218748A patent/AU2020218748B2/en active Active
- 2020-02-04 BR BR112021015321-7A patent/BR112021015321A2/pt unknown
- 2020-02-04 AU AU2020218330A patent/AU2020218330B2/en active Active
- 2020-02-04 JP JP2021546018A patent/JP2022520553A/ja active Pending
- 2020-02-04 EP EP20709842.7A patent/EP3921424A1/en active Pending
- 2020-02-04 CN CN202080012913.9A patent/CN113677799A/zh active Pending
- 2020-02-04 MX MX2021009398A patent/MX2021009398A/es unknown
- 2020-02-04 CN CN202080012911.XA patent/CN113677798A/zh active Pending
- 2020-02-04 US US17/428,510 patent/US20220125860A1/en active Pending
- 2020-02-04 MX MX2021009389A patent/MX2021009389A/es unknown
-
2021
- 2021-07-27 ZA ZA2021/05312A patent/ZA202105312B/en unknown
- 2021-07-27 ZA ZA2021/05310A patent/ZA202105310B/en unknown
- 2021-10-15 US US17/502,716 patent/US20220088094A1/en active Pending
-
2023
- 2023-12-21 AU AU2023285909A patent/AU2023285909A1/en active Pending
-
2024
- 2024-03-11 AU AU2024201593A patent/AU2024201593A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ZA202105312B (en) | 2023-01-25 |
CA3127806A1 (en) | 2020-08-13 |
AU2020218330B2 (en) | 2023-10-12 |
WO2020163398A1 (en) | 2020-08-13 |
CN113677798A (zh) | 2021-11-19 |
MX2021009398A (es) | 2021-11-17 |
US20220125860A1 (en) | 2022-04-28 |
WO2020163398A9 (en) | 2020-09-24 |
CN113677799A (zh) | 2021-11-19 |
JP2022519699A (ja) | 2022-03-24 |
AU2020218748A1 (en) | 2021-08-19 |
BR112021015289A2 (pt) | 2021-10-05 |
US20220127628A1 (en) | 2022-04-28 |
WO2020163284A1 (en) | 2020-08-13 |
AU2020218748B2 (en) | 2023-12-21 |
AU2020218330A1 (en) | 2021-08-19 |
AU2024201593A1 (en) | 2024-04-04 |
US20220088094A1 (en) | 2022-03-24 |
EP3921424A1 (en) | 2021-12-15 |
BR112021015321A2 (pt) | 2021-10-05 |
CA3127898A1 (en) | 2020-08-13 |
EP3921425A1 (en) | 2021-12-15 |
AU2023285909A1 (en) | 2024-01-18 |
ZA202105310B (en) | 2023-01-25 |
MX2021009389A (es) | 2021-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022520553A (ja) | ラクトバチルス・ロイテリ(Lactobacillus Reuteri)菌株を含むプロバイオティック組成物及び使用方法 | |
TWI417054B (zh) | 新穎糞腸球菌ljs-01及其益生用途 | |
CN107075460B (zh) | 具有增强免疫及抗病毒活性的丁酸梭菌菌株及其用途 | |
US7713726B2 (en) | Inhibition of pathogens by probiotic bacteria | |
EP3133152B1 (en) | Novel bacteriophage, and composition containing same | |
US11186815B2 (en) | Methods of using Lactobacillus plantarum strains for protecting animals from pathogenic bacterial infection | |
US11517595B2 (en) | Methods of microbial treatment of poultry | |
Tannock | The lactic microflora of pigs, mice and rats | |
CA2566617A1 (en) | Method and composition for reducing e.coli disease and enhancing performance using bacillus | |
PT2162143E (pt) | Microrganismos do leite de mamíferos, composições contendo os mesmos e seu uso para o tratamento de mastite | |
EP3133153B1 (en) | Novel bacteriophage and composition comprising same | |
RU2394911C2 (ru) | Новые чувствительные к антибиотикам штаммы молочнокислых бактерий | |
PH12015501891B1 (en) | Novel bacteriophage and antibacterial composition comprising the same | |
EP3130669A1 (en) | Novel bacteriophage and composition containing same | |
JP2023543355A (ja) | プロバイオティックバチルス属組成物及び使用方法 | |
JP2010161944A (ja) | 新型カゼイ菌の亜種(sg96)及びこれを含有する菌抑制組成物及びその用途 | |
Economou et al. | Antibiotic resistance in Enterococcus spp. Friend or foe? | |
JP4903559B2 (ja) | 家畜・家禽類又は魚介類の感染防除剤 | |
US10166262B2 (en) | Strain of bacteria and composition comprising the same | |
EP3168292B1 (en) | New lactobacillus plantarum strain amt14 and composition containing the strain of lactobacillus plantarum amt14 | |
KR100593255B1 (ko) | 신규한 바실러스 균주 및 그 용도 | |
US20120225042A1 (en) | Competitive exclusion composition and methods | |
이준영 | Comparative Genomic Analysis of Probiotic Properties of Host-Adapted Lactobacillus spp. Isolated from Pigs | |
TW201715038A (zh) | 新穎的根特節桿菌(arthrobacter gandavensis strains)菌株 | |
Messi et al. | Controversial Aspects Displayed by Enterococci: Probiotics or Pathogens? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211006 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20230123 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20230823 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240115 |